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Zusammenfassung
Aufgrund seines sehr aggressiven Charakters ist schwarzer Hautkrebs, auch
Melanom genannt, der gefa¨hrlichste aller Hauttumore. Dies ist darauf zuru¨ckzu-
fu¨hren, dass Heilung momentan nur durch die chirurgische Entfernung von
lokalisierten, nicht metastasierenden Tumoren erreicht werden kann. Daher
ist eine fru¨hzeitige Erkennung von metastasierenden Zellen und ein besseres
Versta¨ndniss der Mechanismen, die der Metastasierung zugrunde liegen, wich-
tig fu¨r die Entwicklung besserer Therapieansa¨tze.
Melanome entstehen aus entarteten Hautpigmentzellen, die entwicklungsbio-
logisch von der so genannten Neuralleiste abstammen. Aufgrund der Identifi-
zierung von Melanomstammzellen, die Merkmale von ebensolchen Neurallei-
stenzellen besitzen, war das Ziel dieses Projektes deren Einfluss auf die Meta-
stasierung zu untersuchen.
Bedenkt man aber die Komplexita¨t der Melanomentwicklung beim Menschen,
die mehrere aufeinanderfolgende Schritte beinhaltet, konnte dieses Ziel nicht
direkt in Angriff genommen werden. Anstatt dessen musste erst ein neues Mo-
delsystem entwickelt werden, welches den genauen pathologischen Verlauf der
Krankheit widerspiegelte. Um dies zu erreichen haben wir uns ein menschliches
1
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Hautmodel zu Nutzen gemacht, welches es uns ermo¨glicht hat alle Schritte des
Krankheitsverlaufes in Ratten zu rekonstruieren. Diese Schritte umfassten die
korrekte Ansiedlung der Tumorzellen an ihrem Ursprungsort, das Fortschrei-
ten des Krankheitsverlaufes von radialem zu vertikalem Wachstum, sowie die
Entstehung von gut durchbluteten, aggressiven Tumoren.
Aufbauend auf diesem Model haben wir abschliessend noch einige Experimente
bezu¨glich der Rolle von Melanomstammzellen wa¨hrende der Metastasierung
durchgefu¨hrt. Obwohl kein Zusammenhang zwischen den schon beschriebe-
nen CD271Pos Melanomstammzellen und einem erho¨htem Wachstumspoten-
tials festgestellt werden konnte, haben wir einige Hinweise darauf gefunden,
dass CD271Pos Zellen in die Invasion verwickelt sein ko¨nnten. Dies wurde un-
terstu¨tzt durch die Beobachtung, dass in migrierenden Tumorzellen CD271 dy-
namisch reguliert wird. Das ist insofern interessant wenn man bedenkt, dass ein
Prozess aus der Embryonalentwicklung, genannt ’Epithelial-to-Mesenchymal
Transition’, ku¨rzlich als Treibende Kraft fu¨r die Entsehung von Krebsstamm-
zellen identifiziert wurde. Im Bezug darauf konnten wir in ersten Experimen-
ten zeigen, dass der Verlust von E-cadherin, einem bestimmenden Faktor des
EMT Prozesses, ein aggressives Verhalten hervorrufen kann. Interessanterwei-
se wurden in diesen aggressiven Tumoren vermehrt einzelne, invasiven Zellen
gefunden, die stark positiv fu¨r CD271 waren.
Zusammengenommen liefert diese Studie erste Hinweise darauf, dass auch im
Melanom Stammzelleigenschaften dynamisch reguliert sein ko¨nnten. Daru¨ber
hinaus konnten wir durch die Transplantation von genetisch vera¨nderten Zellen
erstmals das Potential des neu entwickelten Modells fu¨r zuku¨nftige Studien
unter Beweis stellen.
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Summary
Due to its extremely high metastatic capacity, cutaneous malignant mela-
noma represents the most fatal skin tumor in industrialized countries. This
is because, up to date, the only possible therapy to cure melanoma remains
surgical excision of localized, non-metastatic primary tumors. Thus, to im-
prove current therapy an early identification of metastasizing melanoma cells
and a better understanding of the mechanisms governing their dissemination
is fundamental.
Melanoma results from transformation of cells of the melanocytic lineage,
which originally is derived from the neural crest. Considering that human
melanoma can arise from melanoma stem cells (MSCs) displaying neural crest
stem cell features, this project aimed at assessing the metastatic capacity of
MSCs and the contribution of neural crest migratory pathways therein.
However, considering the complex nature of melanoma progression involving
several consecutive steps, a novel model system closely resembling human dis-
ease initiation and progression had to be established first. To this end we
employed a tissue engineering approach, which allowed us to recapitulate all
initial steps of disease progression in a humanized environment in-vivo. These
3
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included the incorporation of the tumor cells into their physiological microen-
vironment, transition of radial to vertical growth, and establishment of highly
vascularized, aggressive tumors with dermal involvement.
Based on this novel approach, we conducted several preliminary experiments
addressing the role of melanoma stem cells in metastasis. However, no direct
evidence for an enhanced tumor induction potential for the previously de-
scribed CD271Pos melanoma stem cells was found. Nevertheless, several find-
ings pointed to a potential implication of CD271Pos cells in invasion. In line
with this theory, CD271 expression was discovered to be dynamically regulated
in migrating human melanoma cells. This was of particular interest, consid-
ering that an embryonic signaling cascade termed ’Epithelial-to-Mesenchymal
Transition’ (EMT) was recently shown to induce cancer stem cell behavior.
In accordance with these findings, we were able to obtain first evidence con-
firming that loss of E-cadherin, a determinant of EMT, induces an aggressive
behavior in melanoma. Intriguingly, the resulting aggressive tumors revealed
an abundance of single, invasive cells strongly positive for CD271.
Taken together, this study provides the first experimental evidence indicating
that in melanoma stem cell traits may be dynamically regulated. Furthermore,
in transplanting genetically manipulated cells, we were able to show the great
potential inherent to the developed system for future studies.
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TRP1 Tyrosinase-Related Protein 1
VGP Vertical Growth Phase
7
Introduction
Carcinogenesis: Models and concepts
Cancer epidemiology
Based on global estimations of the World Health Organisation [1], deaths from
cancer account for around 12% of all deaths world wide. This makes cancer one
of the leading causes of mortality and poses, besides cardiovascular diseases,
the most serious health problem for the population. Despite the increasing risk
of developing cancer with age, cancer is not exclusively an age disease. The
global risk of developing cancer at an age younger than 64 years is 10.3% for
males and 9.5% for females [2]. This makes cancer the most common cause of
death in the age group between 40-60 in industrialized countries [3]. With an
estimated increase of global cancer deaths from currently approximately 7.6
millions to 11.5-17 millions over the next 20 years [1], better understanding of
the various forms of cancer remains paramount to improve therapy.
The main treatment possibilities for cancer, up to date, remains a combina-
tion of surgery, radiotherapy and chemotherapy. Whereas advances in these
therapeutic areas have led to a steady decrease in mortality rates over the
last two decades [4], major break-throughs have only recently been achieved
8
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by incorporating specifically designed drugs into standard treatment [5]. This
novel class of drugs are rationally designed based on the growing knowledge of
the molecular pathways driving cancer development and progression. Impor-
tantly, exclusively targeting tumor cells, these drugs are anticipated to improve
efficacy while minimizing toxicity as compared to conventional chemotherapy.
However, despite very successful examples like Imatinib (Gleevec R©, Novartis)
for the treatment of chronic myelogenous leukemia, most target-specific drugs
that enter clinical evaluation fail in producing survival benefits [6, 7]. This
poor translation of basic oncology research to the clinics clearly shows that a
deeper understanding of all aspects of disease progression as well as the devel-
opment of more relevant model systems reflecting the human disease remains
important [6, 7].
The hallmarks of cancer
On a cellular basis cancer arises when tissue cells escape growth control and
start to proliferate indefinitely. For this to happen a cell needs to acquire var-
ious genetic and epigenetic alterations that allow it to overcome a multitude
of intrinsic and extrinsic control mechanisms. Although germ-line mutations
can predispose a person to heritable cancer, most tumors arise as a result of
an accumulation of somatic mutations invoked by etiological agents like smok-
ing, chronic virus infection (e.g. Hepatitis B/C or Papilloma virus), excessive
sun exposure, carcinogenic chemicals etc. Because of this progressive nature
of neoplastic transformation, increasing age constitutes the highest risk factor
for most types of cancer [10]. Currently over 100 distinct cancer types are
known, which can arise in every possible body tissue and carry an almost un-
limited variation of somatic mutations. Paradoxically, it was this remarkable
9
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a
b
Figure 1. The hallmarks of cancer. (a) The six hallmarks of cancer as
originally proposed in 2000 [8]. (b) Over the next decade the concept has been
augmented with two emerging core hallmarks and two enabling characteristics
[9].
complexity that led to the notion of a common organizing principle underlying
neoplastic transformation: The Hallmarks of Cancer (Figure 1a). Based on
the fact that virtually all mammalian cells carry a similar machinery regu-
lating their proliferation and death, these hallmarks represent the six basic
alterations in cell physiology that are essential for malignant growth [8]:
10
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• Self-sufficiency in growth signals
• Insensitivity to growth-inhibitory (antigrowth) signals
• Evasion of programmed cell death (apoptosis)
• Limitless replicative potential
• Sustained angiogenesis
• Tissue invasion and metastasis
Starting from these initial hallmarks, the conceptual framework has been fur-
ther refined over the next 10 years [9]. With respect to that, the most impor-
tant contributions have been linked to two newly emerging core hallmarks and
two enabling characteristics (Figure 1b). Core hallmarks, which are defined as
essential for tumor development, have been proposed to additionally comprise
the capability of cancer cells to reprogram their cellular energy metabolism
to support continuous proliferation [11, 12] and the evasion of immunologi-
cal destruction [11, 9]. In contrast, enabling characteristics are thought to
establish a permissive state, which facilitates the acquisition of the core hall-
marks. As such genetic instability, for example induced by mitotic, oxidative
or metabolic stress [13, 14], has been conjectured to endow cells with the
ability to produce the chromosomal rearrangements required for tumor pro-
gression [15, 9]. Furthermore, it has become increasingly clear that neoplastic
progression is not solely contingent on cell intrinsic changes, but also on contri-
butions of the tumor microenvironment. These have been suggested to include
growth promoting signaling directly exerted by the tumor stroma cells as well
as tumor-promoting inflammation [16].
11
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Figure 2. The clonal evolution of cancer. Induced by a mutation, a
normal somatic cells (N) acquires a selective growth advantage and starts to
overgrow its parental population of cells, which results in a selective sweep.
Subsequent rounds of mutation and selective sweeps drive the stepwise evolu-
tion from a precancerous lesion towards the final neoplasm (depicted as A,B,C)
[17].
The linear model of clonal evolution
Cancer is a genetic disease resulting from the accumulation of aberrations in
the genome of somatic cells. Based on early cytogenetic studies showing that
most tumors originate from a single transformed cell, cancer has been consid-
ered a disease of clonal evolution within the body [14]. First introduced by
Nowell in 1976 [18], the clonal evolution model states that the pathogenesis
of cancer proceeds by sequential steps of mutational events that are subjected
to a Darwinian process of evolution. In a simple representation, this means
that every somatic cell has the same chance to acquire a mutation that confers
selective growth advantage, a so call driver mutation. This mutation enables
it to expand more than the surrounding cells, which over time will result in its
clonal domination - an evolutionary process known as selective sweep. Starting
the next round of neoplastic evolution, eventually an additional driver muta-
tion is introduced into this expanding population, which results in another
12
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selective sweep. Thus, according to this traditional linear model, the accumu-
lation of driver mutations in successive rounds of clonal expansion drives the
stepwise progression from a precancerous lesion to the final neoplasm includ-
ing metastasis (Figure 2).
However, despite being clonal in origin, most human tumors display a substan-
tial genotypical and phenotypical intra-tumoral heterogeneity, which cannot
be explained by the linear model [19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29].
This is because, assuming that every emerging dominant clone results in a
selective sweep, a neoplasm evolving in a linear fashion consequently should
be homogeneous in terms of its genotypic and phenotypic composition. Thus,
resolving the mechanisms underlying these dichotomous observations has been
a central dogma in tumor biology. So far two main concepts have emerged:
the stochastic model of clonal evolution and the cancer stem cell model.
The stochastic model of clonal evolution
For the last three decades the main explanation for the observed intra-tumoral
heterogeneity has been based on an extended clonal evolution model. Different
from the simplistic linear model, in which monoclonal expansion of one dom-
inant clone drives each step of disease progression (Figure 3a), in this model
tumor evolution is considered a stochastic process. Based on their increasing
genetic instability, all cells in an evolving neoplasm accumulate random muta-
tions, which are subjected to Darwinian selection. This renders a neoplasm a
genetically and epigenetically heterogenous entity of clonal populations with
differing proliferative and survival capacities. Within this microcosmos of evo-
lution, all evolving clones are in constant competition with each other, which
consequently leads to the co-existence of multiple genetically divergent tumor
13
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a bLinear Model Mulit-clonal Model
Figure 3. The extended clonal evolution model. (a) In the linear
model, a succession of increasingly aggressive clones sweep through the pop-
ulation and become fixed (upper panel). Consequently, the genetic diversity
should fluctuate, increasing when genetic instability generates new clones in
an expanding population, and decreasing when a new clone strives towards
fixation (lower panel). (b) In the multi-clonal approach several genetically
diverse populations evolve simultaneously. Because the fitness of every clone
depends on its immediate microenvironment, selective sweeps tend to be re-
stricted to individual subpopulations (upper panel). In this model the genetic
diversity increases constantly because genetic sweeps cannot affect the entire
population (lower pannel). Figure adapted from [14, 30].
clones at any time [14] (Figure 3b). Interestingly, according to this model,
selective sweeps homogenizing the entire population are very unlikely to oc-
cur for two reasons. First, some mutations are silent passenger mutations
that do not confer any growth advantage and, therefore, do not present a se-
lectable trait. And second, because the fitness of any given clone presumably
depends on its immediate microenvironment, only selective sweeps within this
particular environment are possible. Consequently, despite being in constant
competition, it is conceivable that several clonal populations can evolve simul-
taneously explaining the frequently observed clonal heterogeneity in human
neoplasms [30, 31]. Interlinked with this genetic heterogeneity, also the ob-
served morphological diversity is explained by the same underlying principle.
14
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Assuming that some of the acquired mutations manifest in a functional and,
therefore, heritable morphological phenotype, selective pressure will also drive
the evolution of multiple, morphologically diverse tumor cell populations.
Importantly, the genetic and phenotypic heterogeneity inherent to most hu-
man neoplasms has been shown to have direct consequences for treatment.
The underlying principle is best demonstrated by depicting the tumor cell
populations on a fitness landscape (Figure 4). In this graphical representation
every possible genotype and its corresponding fitness value is represented by
a single dot. Peaks correspond to the most aggressive genotypes as a function
of proliferation and survival. Considering that a specific genotype (Figure 4,
crosses) can only spawn offspring that are in its genotypic vicinity (Figure 4,
dots), positive selection will only occur when a progeny acquires a mutation
that allows it to go uphill (become more aggressive). As a consequence, if the
genotypic vicinity of a given clone only includes a small fitness peak (Figure
4, green clone), the probability of its progeny to reach a higher peak becomes
very low. Based on this simple model, it becomes obvious that clonal het-
erogeneity results in an increased probability for tumor progression (Figure
4a). This is because clonally heterogeneous tumors are able to explore larger
areas in the adaptive landscape, which increases their chances that one clone
eventually reaches a peak (Figure 4a, blue clone). Intriguingly, the same prin-
ciple also applies for disease recurrence (Figure 4b). Assuming that the main
effect of therapy is imposed by substantially changing the fitness landscape,
the probability of a sub-clone reaching a new peak is again significantly higher
in heterogeneous lesions [14, 30] (Figure 4b, red clone). In favor of this theory,
several examples of sub-clones becoming dominant after treatment have been
documented for lung cancer [32], chronic myeloid leukemia [33], melanoma
15
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[34] and others [14]. As a consequence, the aim of current therapy remains to
eradicate all residual cancer cells in order to minimize the chances of disease
recurrence.
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Figure 4. The consequence of clonal heterogeneity for treatment. In
a fitness landscape every possible genotype is correlated to a fitness value in
a graphical representation. Peaks represent the most aggressive phenotypes,
colored crosses individual clones, and colored dots their respective mutant
offspring. (a) Clonal heterogeneity increases the probability of a tumor to
reach a fitness by sampling a larger area on the landscape. (b) Treatment
renders the originally dominant clone (blue cross) harmless by altering the
landscape. Following treatment, recurring disease results from a genetically
diverse sub-clone (red cross) adapting to the new landscape [30].
The cancer stem cell model
The concept
Opposing the stochastic clonal evolution model, the cancer stem cell theory
stipulates that the phenotypic heterogeneity in tumors arises from an inher-
ent cellular hierarchy rather than random mutagenesis (Figure 5a). In this
model, reflecting their corresponding normal tissue, tumors are sustained by a
pathological counterpart of normal adult stem cells: cancer stem cells (CSC)
[37]. Like normal tissue stem cells, CSC have the potential to self-renew and
16
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Figure 5
17
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Caption Figure 5. The cancer stem cell model. (a) Different from the
stochastic model of tumor development, the cancer stem cell model assumes
that only a small fraction of tumor cells, cancer stem cells, have the ability to
sustain tumor growth. (b) Like their physiological counterparts, cancer stem
cells have the potential to self-renew and to differentiate into phenotypically
diverse progenitor cells with limited proliferative potential. Whether cancer
stem cells can arise by transformation of adult stem cells or de-differentiation
of more restricted progenitor cells is unknown for most types of cancer. Figure
adapted from [35, 36].
to differentiate into phenotypically diverse progenitor cells with limited prolif-
erative potential (Figure 5b). Consequently, tumor growth and maintenance
can solely be perpetuated by the CSC population. Standing at the apex of the
cellular hierarchy, CSCs give rise to differentiated progenitor cells, which con-
stitute the main tumor mass. Although some of these progenitor cells might
retain some limited proliferative capacity, they contribute little to disease pro-
gression and can be considered benign. Obviously, the ramifications of this
theory for treatment are profound. Not the bulk cells of a tumor would have
to be targeted, but the rare CSC population as they are the sole driver of tu-
morigenesis. This would also offer an intriguing explanation for the recurrence
of many cancers after therapy considering that conventional therapy is mostly
designed to eradicate bulk tumor cells (Figure 6). Albeit this would result in a
temporal regression of the tumor mass, already a small population of residual
CSCs resistant to therapy would be sufficient to induce de-novo tumor growth
[38].
Experimental proof
Although the concept of a cancer stem cell has been proposed over a cen-
tury ago by the pathologists Rudolph Virchow [40] and Julius Cohnheim [41]
18
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Figure 6. The consequence of cancer stem cells for treatment. Unless
the cancer stem cell population is eradicated, the chances for recurrent disease
remain high [39].
in their ’embryonal-rest hypothesis’, experimental evidence has only been es-
tablished recently. Pioneered by John E. Dick, CSCs were first identified
in acute myeloid leukemia (AML) [42, 43]. Following the identification of a
primitive CD34+/CD38- hematopoietic stem cells able to recapitulate normal
hematopoiesis in recipient mice, the detection of CD34+/CD38- expressing
cells in human AML patients provided the first indication of a putative CSC
[42]. To address the potential of this putative CSC fraction, AML cells were
fractionated on the basis of their CD34+/CD38- vs. CD34+/CD38+ expres-
sion profile and serially passaged in immuno-compromized, non-obese diabetic
mice with severe combined immunodeficiency disease (NOD/SCID). These ex-
periments revealed that the capacity to transfer human AML to recipient mice,
indeed, resided exclusively within the CD34+/CD38- fraction [42]. Based on
the consistent capacity of CD34+/CD38- AML cells to recapitulate the human
disease independent of the AML subtype they were originally isolated from,
the authors concluded that AML follows a similar hierarchical organization as
normal hematopoiesis [43] (Figure 7a). Importantly, this seminal study not
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only provided the first proof of a CSC population, but also defined the gold
standard for their experimental identification. These steps comprise the the
prospective isolation of a putative CSC fraction from dissociated tumor ma-
terial, the confirmation of their in-vivo tumor initiating capacity as opposed
to bulk tumor cells, validation of their in-vivo self-renewal capacity by serial
transplantation, and proof of their ability to phenotypically regenerate their
original tumor (Figure 7b).
a b
Figure 7. Experimental identification of cancer stem cells. (a) Based
on the similarities to normal hematopoietic stem cells, cancer stem cells were
first identified in human leukemia. (b) Experimental proof for cancer stem cells
requires their isolation from dissociated tumor material, verification of their
exclusive in-vivo tumor induction potential, proof of their capacity to self-
renew in-vivo, and their ability to phenotypically recapitulate their parental
patient tumor. Figure adapted from [44, 45].
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Cancer stem cells in solid tumors
Following the discovery of CSCs in hematopoetic cancers, their existence was
soon demonstrated also in solid tumors [46]. But unlike for hematopoetic tu-
mors, the identification of CSCs in solid tumors has been hampered due to a
lack of definitive assay systems and cell surface markers [44]. This fact is best
reflected by the substantial controversy surrounding the frequency of CSCs
in solid tumor populations. Sometimes ranging from 2% to over 25% in the
same type of tumor [47], the experimental basis for an exact measurement of
the CSC frequency is unknown [48]. This relates to the problem that many
experimental variables like residual immunocompetence of the used animal
host [49, 50], the site of engraftment (unpublished data), co-injection with
extracellular matrix substrates [49] or the amount and quality of injected cells
[51, 52] have been shown to substantially influence CSC measurements. Con-
sidering that the whole foundation of the CSC theory rests on its operational
definition in such experimental model systems (Figure 7b), the development
of relevant humanized model system has been deemed crucial to validate CSC
populations in solid tumors [53].
The origin of cancer stem cells
Despite often confused, the term cancer stem cell does not per se imply that
the neoplastic cell of origin actually is a stem cell. Nevertheless, normal stem
cells have been proposed to be the most likely target for neoplastic trans-
formation. This assumption relies on mathematical models, which predict
neoplastic transformation to be a rare event requiring several rate-limiting
mutations within the same cell [10]. As a consequence it has been presumed
that only the stem cell pool in human tissues persists long enough to accumu-
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late enough genetic and epigenetic alterations for transformation [39]. While
compelling evidence for this theory exists for intestinal [54, 55] and prostate
[56] cancer, for most neoplasms it remains elusive whether cancer stem cells
arise from the transformation of normal stem cells or de-differentiation of more
restricted progenitor cells (Figure 5b). Evidence for the latter model comes
from skin [57, 58] and Chronic Myeloid Leukaemia [59], where more restricted
progenitors were shown to be able to acquire stem cell properties. At present
it appears conceivable that a combination of both mechanism might be opera-
tional during tumor initiation. The most compelling evidence for an integrated
model relates to the fact that the same type of tumor in different patients often
manifests in discrete subtypes with specific properties and expression profiles.
Traditionally, this has been explained by the genetic mutation model, which
assumes that the variety of discrete subtypes is determined by distinct onco-
genic events transforming a common cell of origin (Figure 8a). In contrast,
the hierarchical cell-of-origin model raises the possibility that the different
subtypes arise as a consequence of common mutations transforming different
cell populations along a lineage hierarchy [60] (Figure 8b).
Cancer stem cells vs. clonal evolution
An integrated concept
Regardless of the plethora of literature favoring one model of tumorigenesis
over the other, both major paradigms, the clonal evolution as well as the CSC
model, also harbor several caveats. On one hand, for the CSC model there still
is no direct evidence that the difference between tumorigenic cells and non-
tumorigenic cells emanates from epigenetically induced differentiation instead
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Figure 8. The cell of origin model. (a) In the genetic and epigenetic
mutation model, a variety of distinct oncogenic events is responsible for the
observed tumor subtypes. (b) In the cell-of-origin model tumorigenesis is
driven by a common mutational event. The different subtypes result from
the transformation of different cell population along the lineage hierarchy in
a particular organ [60].
of genetic differences [52]. In fact, contradicting a simple hierarchy-based CSC
model, in breast cancer the tumorigenic CD44+/CD24- stem cell population
was shown to be genetically divergent from the CD44-/CD24+ bulk tumor cells
[61, 62]. On the other hand, also the clonal evolution model has its limitations.
Based on the premise that there are simply more ways to damage a genome
than to improve it, mathematic models show that an increasing mutation rate
due to progressive genetic instability should lead to reduced fitness and, thus,
clonal extinction; an effect known as negative clonal selection [63].
However, given the overwhelming experimental evidence for the clonal origin
of cancer, the mutator theory can hardly be denied as the original driving
force of neoplastic transformation. Thus, attempting to reconcile the clonal
evolution and the cancer stem cell paradigm, an integrated model has recently
been proposed (Figure 9). According to this model, clonal evolution does
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Figure 9
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Caption Figure 9. Clonal evolution and cancer stem cells: an inte-
grated concept. Instead of working on the entire population of tumor cells,
clonal evolution is restricted to the CSC pool. Genetic alterations in conjunc-
tion with microenvironmental niche factors constitute the selective pressure
that drives the evolution of metastatic CSC [64].
occur, but is restricted to the CSC pool. Similar to the multi-clonal model
of tumor evolution (Figure 3b), this would give rise to several genetically
distinct CSC populations defined by their immediate microenvironment [64].
First evidence in support of this model comes from a recent report showing
the stochastic evolution of the CSC population in metastatic colon cancer [65].
Intriguingly, this concept also offers the possibility to reconcile the CSC theory
with the clonally heterogeneous nature of most human cancers. According to
this model, the observed clonal heterogeneity reflects genetically diverse CSC
subpopulations that are in evolutionary competition. Because every CSC pop-
ulation in turn gives rise to a large pool of genetically homogeneous progenitor
cells, the resulting cancers as a whole are heterogeneous.
Tumor cell plasticity and epigenetic stability
However, restricting clonal evolution to a small CSC pool harbors yet another
logic pitfall. Decreasing the number of cells evolution can work on would in
return demand a corresponding increase in the mutation rate. And this of-
ten by two orders of magnitude above the rates that have been described for
human tumor cells [48]. To resolve this paradox, it has been proposed that,
different from a rigid hierarchical model, CSC can arise as a consequence of
tumor cell plasticity. According to this model, the stem cell pool does not rep-
resent a stringent population within a neoplasm, but rather can be induced by
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Figure 10. CSCs as a consequence of a deregulated epigenetic land-
scape. (a) In normal tissue cells and early stage tumors cells retain a stable
epigenetic landscape. Similar to chemical reactions, the loss of free energy
correlates with increasingly stable states. Depicted is the differentiation of
a stem cell (C) to its final, mature cell type (A). (b) The increasing genetic
and epigenetic instability found in late stage cancers causes the epigenetic
landscape to flatten out. This allows cell to move freely between the different
states including that of a stem cell (C) [63].
epigenetic changes contingent on microenvironmental cues [53, 48, 66]. That
tumor cells indeed display a remarkable plasticity in response to their microen-
vironment has been demonstrated by a set of experiments subjecting tumor
cells to an embryonic environment. In this set-up, malignant tumor cells were
shown to be reprogrammed to follow their normal developmental programs
and contribute to normal tissue formation [67, 68]. However, whether this
observed plasticity reflected an inherent trait of pre-existent tumor stem cells
that responded to their original microenvironment or a general feature of all
transplanted tumor cells to acquire a transient stem cell state has not been
addressed.
Clearly the possibility of normal tumor cells switching between stem cell and
non-stem cell states adds yet another layer of complexity to an already am-
biguous concept. However, at the same time, it also poses a promising theory
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to resolve several disparate findings with respect to the frequency and nature
of CSCs [69, 70, 17]. This follows from the fact that, in order to acquire stem
cell features, neoplastic cells need to deregulate their epigenetic landscape.
During the early stages of tumor development cancer cells, like normal tissue
cells, retain a stable epigenetic landscape keeping them in defined, hierarchical
states with a stem cell at the top (Figure 10a). Advancing to late stage tumors,
increasing levels of genetic and epigenetic instability progressively deregulate
the epigenetic landscape causing the discrete states of differentiation to dis-
tort. As a consequence cells acquire the potential to move freely between all
possible states including that of a stem cell (Figure 10b).
Intriguingly, first evidence corroborating this concept was recently identified
in malignant melanoma. In this study the histone 3 K4 demethylase JARID1B
was shown to be essential for tumor maintenance, a typical feature of a CSCs.
But in contrast to the hierarchical CSC model, the expression of JARID1B
was not confined to a specific subpopulation of cells but was found to be dy-
namically regulated [71]. This raises the possibility that epigenetic regulation
might indeed be responsible for the induction of transient stem cell features
in some cancers. Interestingly, a potential mechanism triggering the induction
of such transient, dynamic stem cells has recently been identified in breast
cancer. By inducing a process reminiscent of an embryonic developmental
program termed Epithelial-to-Mesenchymal Transition (EMT), it was demon-
strated that transformed breast epithelial cells adopt CSC properties [72, 73].
This raises the possibility that for some tumors CSCs represent not a fixed
entity, but rather a transient population of cells arising as a consequence of
extrinsically induced epigenetic alterations.
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The ’seed and soil’ hypothesis
Regardless of all recent advances cancer remains a major cause of death. This
is because metastases, rather than primary tumors, are the main cause of
lethality due to cancer. But given the currently limited treatment options for
systemic disease, only a better understanding of the cellular and molecular
programs underlying metastatic progression will improve the chances of sur-
vival.
On a broad scale metastasis can be described as the process, during which
tumor cells disseminate from the primary neoplasm to establish secondary tu-
mors in distant organs. On a cellular basis, the metastatic process has been
envisioned to be a sequence of discrete steps, all of which have to be overcome
to induce metastatic growth at a distant site (Figure 11). These steps comprise
the ability to escape from the primary tumor, enter the vasculature, survive
in the circulation, arrest in a new organ, extravasate into the surrounding
tissue, adapt to the new microenvironment, initiate proliferation, and attract
new blood supply in order to progress to a macroscopic lesion [74]. Based on
this striking complexity, it stands to reason that presumably only a minor-
ity of cells in a neoplasm are equipped with the required attributes to pass
through all these steps. In line with this hypothesis, several seminal studies
showed that the metastatic process is highly inefficient. Interestingly, the in-
efficiency was not caused by limited survival of the disseminated cells but by
their failure to progress beyond the state of a micrometastasis [76, 77]. From
this observation it was concluded that, in addition to cell inherent metastatic
programs, also the environment of the target organ plays an active role in the
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Figure 11. The metastatic process. The metastatic process requires a
series of discrete steps. These include the detachment from the original tumor,
intravasation, survival in the bloodstream, arrest in a new organ, extravasa-
tion into the surrounding tissue, adaptation to the new microenvironment,
proliferation at the new site, and establishment of new blood supply [75].
tropism of metastatic disease. Interestingly, at the time these experiments
were performed, the underlying concept had been postulated over a century
ago. It was first described by the the English surgeon Stephen Paget in 1889,
who noted a discrepancy between the frequency of metastases and the relative
blood supply in certain organs. This observation of a non-random pattern of
metastasis led him to postulate that ’when a plant goes to seed, its seeds are
carried in all directions; but they can only live and grow if they fall on conge-
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nial soil’ [78]. This statement founded what today, 122 years later, is known
as the as the ’seed-and-soil’ hypothesis. It states that metastasis depends on a
favorable interaction between the cancer cells, ”the seeds”, and the microenvi-
ronment of the target organ, ”the soil”. Although challenged 40 years later by
James Ewing, who proposed that the observed organ specificity is exclusively
attributed to mechanical forces and circulatory patterns between the primary
tumor and the secondary site [79], Paget’s theory has stood the test of time
[75]. Validated by a set of in-vivo experiments performed in the 1970s, it was
shown that, although mechanical arrest in the capillary bed of distant organs
does occur, the progression to a macroscopic lesion is dependent on a favorable
environment provided by the target organ [75, 80]. Thus, at present a combi-
nation of both theories appears most likely. Instead of actively ’seeking out’
a specific organ, circulating cancer cells are passively transported along until
they are arrested in a capillary bed due to physical size restrictions. At this
point their subsequent growth will depend on favorable molecular interactions
between the cancer cells and the environment of the new organ [74].
Metastatic heterogeneity and metastatic inefficiency
Following the observation that tumors display a strong intra-tumoral hetero-
geneity [30], several seminal studies started to explore the implication of this
cellular heterogeneity on tumor progression [80]. From these studies two funda-
mental concepts arose, that of metastatic heterogeneity and that of metastatic
inefficiency. The first model refers to the findings that individual cells within
a tumor display a divergent propensity to metastasis [81]. The latter refers to
the fact that the metastatic process overall is inefficient due to the stochastic
nature of the genetic events underlying the acquisition of metastatic traits.
Taken together, this points to the existence of specialized metastatic cells,
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which are equipped with an enhanced capability to adapt to a new microenvi-
ronment and initiate de-novo tumor growth at a distant site [76, 82]. This is
further corroborated by the fact that most metastases are monoclonal in origin
[83, 84, 85, 86, 87, 88, 89]. However, the origin and nature of such specialized
cells driving systemic disease remains elusive. But corresponding to the main
concepts underlying tumorigenesis described above, only two potential mech-
anisms are conceivable, clonal evolution or cancer stem cells.
Clonal evolution and metastasis
Based on the clonal evolution model, systemic disease could be the final result
of two differing processes, linear or parallel evolution of a metastatic clone.
According to the linear model, metastatic cell dissemination would be the
last step of tumor evolution. Bestowed with all malignant traits necessary to
conquer a distant sites, metastatic cells are considered the pinnacle of evolu-
tion in a primary neoplasm [18]. In contrast, according to the parallel model,
early disseminated tumor cells evolve independently parallel to the primary
tumor [90]. Practically the difference between the two models should manifest
in the clonal relationship between the primary tumor and the corresponding
metastases. In the linear model, reflecting the late dissemination of already
fully metastatic cells, the metastatic tumors should display a close clonal re-
lationship to the primary tumor. In contrast, following the parallel model,
metastases should represent genetically divergent clones [30].
Reflecting the long standing relationship between tumor size and metastasis,
which forms the basis for the pathological tumor, nodes, metastasis (TNM)
staging, linear progression has been accepted as the more likely mechanism.
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Nevertheless, several conceptual caveats have challenged the idea of linear
progression. Based on tumor growth rates, mathematical models predict that
for linear progression to occur metastatic growth rates would have to exceed
that of their primary tumors by far in certain conditions, for which there is
no evidence [90]. Moreover, metastatic lesions already present in early stage
tumors (T1M1 or T2M1) or growing without a detectable primary tumor are
difficult to reconcile with linear progression. And last but not least, considering
a Darwinian mode of selection towards the emergence of a metastatic clone,
the assumption in itself presents a paradox. If metastatic clones leave the
primary tumor, the primary tumor would suffer a decrease in fitness due to
the loss of its fittest offspring, which eventually should result in its extinction
[14]. Although evolutionary pressure towards dispersal appears conceivable
based on the limitation of space and nutrients in a growing neoplasm, this
conceptual problem has not yet been resolved. So far both models seem valid,
as there is experimental evidence in favor of both theories emerging [87, 21,
91, 24, 92, 93, 94].
Cancer stem cells and metastasis
Defined as the only sub-set of cells capable of initiating de-novo tumor forma-
tion, it is clear that CSCs offer an auspicious candidate for the induction of
metastasis. But besides this, CSCs would also offer an intriguing explanation
for many peculiarities inherent to the metastatic process [37]. For example,
like their ’normal’ counterparts, CSCs are thought to reside in a distinct mi-
croenvironment called the ’stem cell niche’, which regulates stem cell traits like
proliferation, differentiation, and apoptosis resistance [95]. Strikingly, this idea
is congruent with Paget’s ’seed and soil’ hypothesis, if one assumes that dis-
tinct CSC niches can only be found in particular organs. Along this line also
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Figure 12. Epithelial-to-mesenchymal transition. Undergoing an
epithelial-to-mesenchymal transition (EMT), benign carcinoma cells acquire
the potential to push through the basement membrane and invade the un-
derlying dermis. At a secondary site the reverse process, an mesenchymal-to-
epithelial transition (MET), governs the progression from micrometstases to
macrometastatic growth [96].
the observed dormancy of metastases, often evolving decades after resection
of a primary tumor, could be explained. Residing in a niche, disseminated
CSCs initially stay quiescent until a sudden change in the microenvironment
activates their lethal potential.
Intriguingly, the strongest argument for the implication of CSCs in the
metastatic process is, like the CSC concept itself, adapted from developmen-
tal biology. As such an embryonic migratory process called ’the epithelial-to-
mesenchymal transition’ has been proposed to constitute a major determinant
for the progression of benign adenomas to malignant carcinomas [96]. During
EMT tightly adherent, non-migratory, polarized epithelial cells transform into
lose, unpolarized mesenchymal cells displaying an inherent migratory poten-
tial (Figure 12). Considering this, it appears conceivable that CSCs could
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exploit remnants of this embryonic signaling pathways in order to dissemi-
nate, adapt, and survive at distant sites. However, at present convincing data
proving the implication of CSC in the metastatic process remains fragmentary
[97]. But nevertheless, first evidence for a link between EMT and CSCs has
emerged from breast cancer. Surprisingly, in these studies EMT was no found
to confer migratory potential to CSCs, but was identified as the determinant
inducing CSC traits in transformed mammary epithelial cells [72, 73]. In this
dual role, the EMT transdifferentiation program was suggested to serve as a
regulatory interface, which concomitantly controls migratory and tumor in-
ducing potential [72, 98] in response to contextual signals provided by the
microenvironment [99].
Technical considerations studying metastasis
Metastasis is a systemic process ’hidden’ away in the body and, therefore,
notoriously difficult to observe. Thus, to faithfully model the complexity of
the metastatic process, special care has to be applied choosing a relevant
model system. Unfortunately, the most frequently used experimental metasta-
sis models, intravenous and subcutaneous injections into mice [100], have been
questioned with regard to their fidelity of the human process [90, 101, 102, 103].
As a consequence, it has been proposed that, in order to improve the relevance
of the findings, the applied in-vivo models should mimic the autochthonous
situation of tumor progression as closely as possible [104, 102, 103]. However,
given the lack of such model systems for most human cancers, studying the
metastatic process remains technically challenging.
Another difficulty impeding the investigation of metastatic traits is the ge-
netic and epigenetic heterogeneity found in primary and secondary lesions.
This applies in particular to micro-array studies, in which rare metastatic
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traits are prone to submerge in the background noise inherent to a heteroge-
nous sample [80]. This was made clear by a study sampling different areas
within cervical tumors. Interestingly, whereas the majority of the genes in
different regions of the same tumor were expressed relatively homogeneously,
there remained a significant heterogeneity among a subset of genes involved
in transcriptional regulation and cellular metabolism [105]. Thus, conducting
micro-array analysis the intra-tumoral heterogeneity as well as the presence
of non-tumor stroma cells has to be taken into account by sampling multiple
areas from, if applicable, several patients [80].
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Melanoma as a model system
With respect to the myriad of contradictory reports surrounding the concept
of CSCs as well as their potential implication in metastasis, we chose human
malignant melanoma to address some these open questions. The rational for
using melanoma lies in its neoplastic origin, the melanocytes. During develop-
ment the melanocytic lineage originates from a transient population of highly
migratory embryonic stem cells, the neural crest (Figure 13a). Intriguingly,
many processes attributed to metastasis formation are reminiscent of embry-
onic neural crest development, during which neural crest cells migrate from
their sites of origin, proliferate, and colonize distant sites in specific locations.
Considering these similarities, it is conceivable that its strong propensity to
metastasize reflects an intrinsic property of some melanoma cells able to ex-
ploit inherent developmental signaling cues. Among these, the most promising
relates to the process of EMT, which is not only the initiating event of neural
crest delamination from the neural tube, but also a prerequisite for the malig-
nant progression of carcinomas [96]. In view of the, albeit conflictive [70, 106],
studies reporting the identification of melanoma stem cells (MSCs) resembling
a neural crest stem cells (NCSC) [51, 107], potential parallels between MSCs,
Neural Crest development, and metastasis represent the conceptual framework
of the project described here.
Melanoma epidemiology
Over the last 6 decades melanoma has shown a dramatic increase in incidence,
now ranking among the top 10 cancers in North America, Europe, Australia
and New Zealand, the main regions of occurrence [1]. The strongest risk factors
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Figure 13. The developmental origin of melanoma. (a) Undergoing
an archetype EMT, neural crest stem cells delaminate from the dorsal part
of the neural tube during early embryonic development. Upon delamination,
they migrate along distinct pathways to various sites throughout the embry-
onic body and differentiate into various cell types like neurons, glia, connective
tissue, cartilage, bone, pigment cells and others. Neural crest stem cells ex-
press the low-affinity neurotrophin receptor CD271 (also called P75NTR) and
the transcription factor Sox10. (b) Human melanoma cells express the mela-
noma associated markers HMB45, MelanA and S100. (c) Staining of a human
melanoma xenograft for the neural crest stem cell marker CD271 / Sox10 and
neural crest derivatives like smooth muscle cells (SMA) or neuronal cells (bIII-
tubulin) reveals its close relationship to the neural crest. Counterstaining with
GFP excludes that the observed cellular heterogeneity results from infiltrating
host cells. Scale bars, 100µm.
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to develop melanoma comprise a family history of melanoma, multiple benign
or atypical nevi, and a previous melanoma. Additional risk factors include im-
munosuppression, sun sensitivity, and exposure to ultraviolet radiation [108].
Interestingly, the hazardous effect of ultraviolet radiation, the main etiological
factor for the induction of melanoma, appears to be dose-dependent. As such
melanoma occurs most frequently in individuals with sporadic intense expo-
sure and heavy sunburns. The underlying reason for this has been proposed to
result from genetic damage invoked by intense exposure as compared to DNA
damage protection induced by chronic or low-grade exposure [109].
Melanoma classification
Melanoma progression
Normal melanocytes Radial Growth Phase Vertical Growth Phase
Figure 14. Melanoma progression. Melanoma progression follows a well
described sequential pattern. Upon transformation normal melanocytes start
to proliferate within the confines of the epidermis (Radial Growth Phase).
Accumulating aggressive traits the cells acquire the ability to penetrate the
underlying basement membrane and start to invade the dermal compartment
and surrounding vasculature (Vertical Growth Phase).
Histopathologically melanoma develops in a multistep fashion first described
by the dermatologist Wallace H. Clark jr. in 1984 [110]. Starting with normal
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melanocytes or a benign nevus, the begin of neoplastic transformation first
manifests as a dysplastic nevus with structural atypia. Accumulating further
mutations, these dysplastic nevi then pogress to radial growth phase (RGP)
melanoma, typically characterized by a lateral growth pattern confined to the
epidermis. During RGP, the cells acquire invasive traits and progress to the
last step, the vertical growth phase (VGP). During the vertical growth phase
expansive nodules of malignant cells penetrate the basement membrane and
start to invade the underlying dermal tissue and surrounding vasculature [108]
(Figure 14).
Tumor-Node-Metastasis (TNM) staging
This well documented sequential pattern of disease progression has been imple-
mented into the clinical routine to define treatment and estimate prognosis.
Staging of cutaneous melanoma follows the American Joint Committee on
Cancer (AJCC) tumor-node-metastasis (TNM) classification [111]. The key-
stones of these guidelines are the primary tumor thickness (T), the number
of infiltrated regional lymphatic nodes (N), and detectable distant metastatic
lesions (M). Further sub-classification include non-ulcerated (a) and ulcerated
tumors (b), size of nodal metastases, location of distant metastases, and ele-
vated serum lactate-dehydrogenase (LDH) levels (Figure 15a). Based on these
criteria patients are separated into 4 groups with decreasing survival estimates
[111] (Figure 15b,c).
The main treatment for melanoma is surgical resection of the primary tu-
mor with an increasing margin of surrounding skin depending on the tumor
thickness. While this approach proves effective for patients with small localized
tumors, the options for the treatment of metastatic disease are limited. As tra-
ditional cytotoxic chemotherapeutics have not proved effective [112], the main
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Figure 15. Melanoma staging. (a) TNM staging categories according to
the American Joint Committee on Cancer (AJCC). (b) Based on the TNM
staging patients are subdivided into the stages I-IV. (c) Survival estimate in
relation to the anatomic staging [111].
adjuvant therapies are high dose of Interferon-α for stage III and Interleukin-
2 treatment for Stage IV disease, both of which have shown limited efficacy
in clinical trials [112]. This lack of effective treatment has to be considered
the main reason for the poor prognosis for patients facing metastatic disease
(Figure 15c). Thus, in order to improve patient survival, new treatment strate-
gies based on a better understanding of the mechanisms underlying melanoma
progression are needed.
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Skin-color and melanoma susceptibility
The body’s main defensive measure against ultraviolet radiation is the tan-
ning response. Induced by signaling from α-melanocyte-stimulating hormone
(α-MSH) binding its receptor, the melanocortin receptor 1 (MC1R), ultravio-
let light triggers the expression of the microphthalmia-associated transcription
factor (MITF). MITF in turn induces pigmentation by transcriptionally ac-
tivating the genes underlying melanin synthesis: tyrosinase-related protein 1
(TRP1) and dopachrome tautomerase (DCT) [113]. The subsequent transfer
of melanin to keratinocytes protects the skin from sun induces damages by ab-
sorbing and dissipating ultraviolet energy [108]. Interestingly, reflecting their
increased melanoma susceptibility [114], light-skinned and redheaded people
often carry a germ-line polymorphisms reducing the activity of MC1R [115].
Genetic events underlying melanoma genesis
While detrimental alterations of the sun protective system might facilitate
melanoma development, they do not constitute the underlying events driving
neoplastic transformation. The most prominent pathway mutated in mel-
anoma is the mitogen-activated protein kinase (MAPK) signaling pathway,
the main function of which is to relay cell-cycle progression and proliferation
signals of numerous growth factor receptors. Activating mutations can be con-
ferred by either a leucine or lysine for glutamine substitution at position 61
(Q61L/K) in N-Ras [116] or a glutamic acid for valine substitution at position
600 (V600E) in B-Raf [117] (Figure 16a). With a penetrance of over 70%,
constitutive activation of the MAPK pathway represents the most frequent
somatic mutation in melanoma and is considered a crucial event in the neo-
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plastic transformation of melanocytes. However, based on the high frequency
of B-Raf mutations also in benign and dysplastic nevi [118], it has been sug-
gested that mutational activation of the MAPK pathway is a prerequisite, but
in itself not sufficient for melanoma initiation. The reason for this has been
mostly attributed to the effect of oncogene-induced cell senescence [119], a
protective mechanism active in melanocytes, which prevents the progression
of nevi to cancer [119].
Thus, in order to accomplish full malignancy additional cooperating genetic
events need to be introduced on top of the MAPK pathway [121, 122]. The
first potential candidate was identified by linkage-analysis studies of families
with a high incidence of melanoma. These studies revealed a high prevalence
of germline mutations in the CDKN2A locus in these families [123]. Located
on chromosome 9p21, CDKN2A encodes two distinct tumor-suppressor pro-
teins involved in the regulation of the cell cycle, INK4A (also p16) and ARF
(also p14 or p19 in mice) (Figure 16b). INK4A blocks the transition of the
cell cycle from G1 to S phase by inhibiting CDK4/6. In this function it is con-
sidered a main regulatory element suppressing the proliferation of cells with
damaged DNA or activated oncogenes [120, 113] (Figure 16c). The second
splice variant of the CDKN2A locus, ARF, participates in the core regulatory
function controlling p53 levels. By inhibiting MDM2-mediated ubiquitylation
and degradation of p53, it stabilizes and enhances intra-cellular p53 levels. In
response to a damaged genome, this accumulation of p53 triggers cell cycle
arres, which allows for subsequent DNA damage repair or the induction of
apoptosis [120, 113, 108] (Figure 16c).
Based on this cell-cycle regulatory function of the CDKN2A locus products,
it was proposed that the escape from growth inhibition in response to over-
42
Melanoma Melanoma initiation
p14ARF
p16INK4a
CDNK2A locus
a
b
c
Figure 16
43
Melanoma initiation Melanoma
Caption Figure 16. Key pathways driving the neoplastic transfor-
mation of melanocytes. (a) The most prominent pathway mutated in mel-
anoma is the MAPK pathway. Constitutive activation is mostly achieved by
either an activating N-Ras of B-Raf mutation. Another frequently found muta-
tion inactivates the phosphatase PTEN leading to augmented AKT signaling
(b) Based on alternative splicing the CDKN2A locus on chromosome 9p21
encodes two tumor-suppressor proteins, INK4A and ARF. (c) Both splicing
variants are involved in the regulation of cell cycle progression [120].
active MAPK signaling could be achieved by deregulating cell cycle control
mechanism. Validating this hypothesis, the functional relationship between
enhanced proliferation and loss of cell cycle control in melanoma pathogene-
sis has been demonstrated in a variety of studies. In several genetic mouse
models constitutive active MAPK signaling in conjunction with loss of either
INK4A or ARF activity has been shown to induce melanoma growth [124].
Furthermore, in human melanocytes the expression of B-RafV600E was found
to induce cell senescence by upregulating INK4A [119], while loss of INK4A
or ARF in combination with activated N-Ras or B-Raf resulted in the devel-
opment of invasive melanoma [125].
However, mutations of CDKN2A occur in only a portion of familial and spo-
radic melanoma. A second homozygous deletion frequently found in melanoma
relates to the PTEN locus on chromosome 10 [126]. Phosphatase and tensin
homolog deleted from chromosome ten (PTEN) encodes a tumor suppressor
phosphatase, which attenuates signaling from a variety of growth factor recep-
tors depending on phosphatidylinositol phosphate (PIP3) as a docking site for
downstream effector proteins. In response to a stimulus, the phosphorylation
of PIP2 to PIP3 activate the protein kinase B (PBK or Akt), which in turn
acts as a master regulator promoting proliferation and survival. Counteract-
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ing these growth and survival effects, PTEN blocks the activation of Akt by
dephosphorlyating PIP3 (Figure 16a). Loss of PTEN function, therefore, leads
to an enhanced survival and proliferation potential of transformed cells and, in
conjunction with activated B-RafV600E, has been shown to induce metastatic
melanoma in genetic mouse models [127].
Targeting B-raf and N-ras with specific inhibitors
Given the high penetrance of B-Raf and N-Ras mutations in melanoma, great
hopes for therapy lie in specifically targeting these mutant proteins. Based
on the failure of unspecific N-Ras and B-Raf inhibitors in clinical phase II
trails [128], novel inhibitors specifically targeting the most common mutations
in N-Ras and B-Raf are currently developed. The most promising candidate
is Zelboraf R©(vemurafenib), a drug designed to specifically block the activity
of mutant B-RafV600E. It has recently been granted market approval by the
american Food and Drug Administration (FDA) based on its encouraging re-
sults in patients with metastatic melanoma carrying a B-RafV600E mutation
[112, 129].
However, despite these promising results, there remains a fundamental discrep-
ancy between a transient clinical remission and stable cure. Based on some
cases showing relapse, a recent study confirmed that melanoma cells can ac-
quire resistance to B-RafV600E inhibition by up-regulating Receptor Tyrosine
Kinases or N-Ras activity [130]. Thus, a major focus in melanoma research has
to remain the elimination of all residual disease. At present, however, there
is a discordance on how this should be achieved best. While melanoma stem
cells (MSC) offer the best explanation for the therapy resistance of melanoma,
their existence has been questioned by several conflicting reports [70].
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Melanoma stem cells
The eclectic nature of MSCs
While the cancer stem cell model has been accepted for several solid tumors
[131], the data regarding the nature and existence of MSCs is contradictory
[70]. Following the identification of MSCs based on the heterogeneous expres-
sion of a variety of cell surface proteins including CD20 [132], CD133 [133],
MDR1 [134], and ABCB5 [135], two seminal studies performed in Sean Morri-
son’s lab gave reason to challenge the entire cancer stem cell paradigm [50, 49].
This relates to the fact that the frequency of human melanoma initiating cells
originally was anticipated to be very low (0.0001%) [135, 49]. However, tradi-
tionally all these studies haven been performed in NOD/SCID recipient mice,
which have impaired T and B cell lymphocyte development but retain natural
killer (NK) cell activity. Based on the observation that normal hematopoi-
etic cells engraft more efficiently in NOD/SCID mice also lacking NK cells,
NOD/SCID/IL2rγnull (NSG) mice, these two studies showed that also the en-
graftment efficiency of human melanoma cells was contingent on the residual
immuno-competency of the employed recipient animals [50, 49]. Showing a
tumor initiating capacity of up to 1 in 4 cells in NSG mice, these studies
called the dogma of a rare population of tumor initiating cells in melanoma
into question. Furthermore, no correlation between tumor initiating capacity
and expression of the previously published MSC markers could be established,
which raised the possibility that all the previous findings might be artefacts
of their respective model systems.
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A developmental approach
These contradictory findings started a debate on the relevance of the model
systems and technical procedures used to identify MSCs, which has not been
resolved yet [48]. However, considering that a CSC is not only defined by
its ability to initiate de-novo tumor growth, but also by its potential to self-
renew in-vivo and re-establish the cellular composition of its parental tumor
[36] (Figure 7b), assessing the tumor induction capacity as the only measure of
a putative CSC is not entirely accurate. Taking into account that the defini-
tion of CSCs was originally inspired by a frequent intra-tumoral heterogeneity,
a fundamental property of a CSC has to include the ability to phenotypically
recapitulate its original patient tumor. Addressing this issue, a recent study
compared melanoma xenografts in NOD/SCID and NSG mice with respect to
their cellular composition [51]. Based on the assumption that a putative MSC
resembles a neural crest stem cell, from which the melanocytic lineage orig-
inates during embryonic development (Figure 13a), all parental tumors and
derived xenografts were assessed for their expression of neural crest related
markers [51] (Figure 13c). Intriguingly, analysis of 19 independent patient
metastases revealed a stable expression pattern for various neural crest deriva-
tives as well as the NCSC marker CD271 and Sox10 [136, 137]. Providing the
experimental basis, this robust pattern of cellular heterogeneity was used to
analyzed potential differences in xenografts propagated in either NOD/SCID
or NSG recipient mice. Strikingly, whereas xenografts growing in NOD/SCID
mice faithfully recapitulated the cellular heterogeneity of their respective pa-
tient tumors, xenografts arising in NSG mice revealed discrepancies in their
phenotypical composition. Based on these findings, the influence of the em-
ployed host animals on a putative MSC population was assessed. To this end
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human melanoma cells were separated on the basis of CD271 expression, a
controversially discussed MSC marker [107, 50, 49]. Following subcutaneous
injection into either NOD/SCID or NSG mice the tumor induction capacity,
the self-renewal capacity in-vivo, and the cellular composition of the resulting
xenografts induced by CD271Pos and CD271Neg melanoma cells were analyzed.
Interestingly, in line with previous findings [50, 49] NSG mice provided a host
environment permissive for tumor induction independent of CD271 expres-
sion. But strikingly, the resulting xenografts lacked the ability to self-renew
and faithfully recapitulate the cellular heterogeneity of their parental tumors
[51]. In contrast, using NOD/SCID mice, CD271Pos melanoma cells showed
all attributes expected of a MSC such as exclusive tumor induction potential,
self-renewal capacity in-vivo, and the ability to recapitulate their parental tu-
mors [51]. Taken together with an independent study corroboration the highly
increased tumorigenic potential of CD271Pos melanoma cells [107], it appears
likely that melanoma cells positive for CD271, nevertheless, represent a gen-
uine MSC population.
Melanoma metastasis
Using microarray technologies to study melanoma metastasis
Facing extremely poor prognosis, metastatic disease is the most fearsome as-
pect for patients diagnosed with melanoma (Figure 15c) [111]. Thus, great
hope for a better understanding of the pathways underlying melanoma pro-
gression has been placed in the rapidly advancing microarray technologies.
However, although several comparative analyses of human nevi, VGP, RGP
and metastatic melanoma samples have revealed a multitude of differentially
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regulated genes involved in cell-cycle control, cell-cell and cell-matrix interac-
tions, cytoskeletal organization, and cell surface receptor signaling pathways
[138], they all have failed in producing reliable results with respect to fu-
ture treatment [139, 140, 141, 142, 139, 143, 144] (see also section ’Technical
considerations studying metastasis’). Therefore, in order to improve our un-
derstanding of the mechanisms rendering melanoma one of the most aggressive
forms of cancer, new approaches need to be established.
Metastatic propensity
In principle two distinct molecular mechanisms could explain the proclivity of
melanoma to metastasize. First, a strong genetic instability could render mel-
anoma cells highly susceptible to alterations driving metastatic dissemination.
Or second, melanoma cells could generally be equipped with an intrinsic pre-
disposition to metastasize. Although both mechanisms appear equally feasible,
it is the latter model that offers the more promising concept. This follows from
the developmental origin of the melanocytic lineage. As a progeny of highly
migratory neural crest stem cells (Figure 13a), the implication would be that
elements of the molecular neural crest migratory circuit could be re-activated
during melanoma progression. Taken together with the recent identification
of MSCs showing NCSC-like features [107, 51], the possibility that melanoma
progression indeed reflects its developmental origin appears feasible. This is
further supported by several studies associating the MSC-marker CD271 with
enhanced invasion and metastasis [145, 146, 147, 148, 149, 107, 51]. However,
among these studies only one directly correlated MSCs to metastatic disease.
In this study, using human tissue microarrays, the frequency of CD271/Sox10-
positive MSCs in primary tumors was found to be inversely related to survival
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[51] (Figure 17).
Figure 17. The effect of melanoma stem cells on survival. The fre-
quency of MSCs expressing CD271/Sox10 correlates with metastatic potential
and, consequently, decreased survival in patients [51].
The embryonic neural crest and melanoma metastasis
Neural crest EMT and melanoma metastasis
Given the robust, neural crest associated phenotypical heterogeneity identified
in several primary patient tumors as well as metastases [51], these findings are
difficult to reconcile with the idea of stochastic genetic alterations driving mel-
anoma metastasis. It rather points towards a directed process, which involves
stringent cellular programs that are able to induce a consistent morphological
phenotype across a wide variety of patients. Intriguingly, the most prominent
candidate for such an underlying program is, yet again, conceptually derived
from embryonic neural crest development. As such, key processes of metastasis
formation are reminiscent of neural crest EMT, which governs the delamina-
tion of neural crest cells from the neural tube. Upon EMT, neural crest cells
adopt a remarkable migratory capacity, which allows the cells to disseminate
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throughout the embryonic tissue and to colonize even distant sites, where they
differentiate into specialized cells types. Based on the striking similarities to
the metastatic process, it has been suggested that the aggressive nature of mel-
anoma reflects the ability to recapitulate elements of the molecular network
underlying neural crest EMT [150, 151]. With respect to the circumstantial
evidence suggesting a hierarchical organization of melanoma, this could imply
that the strong propensity to metastasize is a consequence of few ’metastatic’
MSCs able to exploit inherent developmental signaling cues. However, whether
in this scenario the ability to undergo EMT is an exclusive trait inherent to
a putative MSC fraction or a causative factor inducing stem cell behavior in
response to microenvironmental cues remains to be addressed (for detailed
discussion see section ’Tumor cell plasticity and epigenetic stability’).
The induction of the neural crest EMT
Considering the potential implication of neural crest EMT pathways underly-
ing melanoma metastasis, novel insights might be gained by considering the
role of known EMT pathways in the context of melanoma progression (Fig-
ure 18). The induction of EMT in neural crest cells is controlled by BMP4,
which activates the canonical Wnt pathway leading to Cyclin D1 expression,
G1/S transition, and neural crest delamination [152]. The onset of neural crest
specification and migration is controlled by a gradient of the BMP inhibitor
Noggin, which has also been shown to block invasive growth of a murine mel-
anoma cell line upon transplantation into the optic cup of a chick embryo
[153]. Consistent with these findings, BMP4 and BMP7 were shown to be
overexpressed in primary metastatic melanoma [154]. Interestingly, inhibition
of BMP 4 and 7 resulted in reduced in vitro invasiveness suggesting that a
tumor microenvironment mimicking the dorsal neural tube might drive tumor
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cell dissemination by inducing EMT. Furthermore, Wnt signaling, a key regu-
lator of development and cancer [155] links the BMP/Noggin signaling axis to
regulation of another group of crucial EMT regulatory elements: the calcium-
dependent intercellular adhesion molecules of the cadherin super-family [156].
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Figure 18. Neural crest EMT pathways. Known molecular pathways
controlling the delamination of neural crest cells from the neural tube.
The role of N-Cadherin
One of the most important cadherin implicated in neural crest development
is N-cadherin. Initially expressed in the entire neural tube, it is lost upon
EMT of neural crest cells [157]. Interestingly, full length N-cadherin inhibits
the onset of neural crest EMT by sequestering β-catenin and, thus, block-
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ing Wnt signaling [158]. However, extracellular cleavage of N-Cadherin by
the BMP4-activated metalloproteinase ADAM10 generates an intracellular C-
terminal fragment (CTF1), which is further processed by a γ-secretase to yield
the active signaling compound CTF2 [159]. This attributes a dual function to
N-cadherin in promoting EMT: cleavage of the extracellular domain reduces
cell-cell adhesion, while translocation of the resulting CTF2 to the nucleus
stimulates cyclin D1 transcription and neural crest delamination [158]. Sig-
naling elicited by CTF2 also leads to increased β-catenin expression, adding
another level of complexity to the crosstalk between Wnt/β-catenin and N-
cadherin signaling.
The role of E-Cadherin
Although not crucial for neural crest EMT, E-cadherin is considered the main
determinant of progression in epithelial carcinomas [160]. Its expression is
directly controlled by the zinc-finger transcription factor Snail, which itself is
an important mediator of metastasis [161]. Interestingly, Snail is among the
earliest markers observed in prospective neural crest cells upon induction by
BMP4/Wnt [152]. Moreover, inherent β-catenin-like canonical motifs places
it under the control of the Wnt dependent GSK-3β degradation pathway sug-
gesting that stabilization of Snail, either through mutation in the degradation
pathway or constitutively active Wnt signaling, might trigger disease progres-
sion [162]. Consistent with this idea, Snail was found to induce the neural
crest markers Slug, Twist and Fox3D [163], all of which have been linked
to neural crest EMT and migration [152] as well as melanoma progression
[164, 139]. Finally, another Wnt-dependent pathway involving Wnt5A acting
through Protein Kinase C rather than β-catenin has been associated with in-
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creased Snail expression and melanoma cell motility [165].
The role of Snail and SoxE transcription factors
During embryonic neural crest development, Slug/Snail is able to induce EMT
only in conjunction with a member of the SoxE transcription factor super-
family [166], pointing to a possible role of SoxE factors in driving tumor
progression in melanoma, as shown for Sox9 in prostate cancer [167]. Sim-
ilarly, SoxE transcription factors are able to induce neural crest delamination
upon concomitant activation of small RhoGTPases, suggesting also alternative
molecular pathways promoting neural crest EMT. In line with this hypothesis,
the small RhoGTPases Cdc42 and Rac1 have been implicated in membrane
protrusion formation associated with invasiveness of a human melanoma cell
line [168].
The role of the low affinity neurotrophin receptor CD271
Although widely used as a marker for NCSCs, the functional role of of the low-
affinity neurotrophin receptor CD271 (or P75NTR) is not well characterized.
As a member of the tumor necrosis factor (TNF) receptor family, it has mainly
been associated with mediating neuronal cell death. However, based on some
idiosyncratic structural and behavioral features, CD271 is considered to have
multiple functions [169]. As such it acts as a cooperative facilitator of TrkA
signaling, the nerve growth factor (NGF) receptor. In conjunction with TrkA,
CD271 builds a high affinity binding site for NGF [170], which has been impli-
cated in regulating cell survival [170]. In addition, CD271 was shown to play
a role in several cellular pathways regulating survival, apoptosis and axonal
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outgrowth [171, 172, 173]. However, missing an active kinase domain, it is not
entirely clear how CD271 affects these processes. While signaling has been sug-
gested to occur largely through association with cytoplasmic adaptor proteins
[172], CD271 has also been shown to undergo regulated intramembrane prote-
olysis [174]. During this process, similar to the N-Cadherin intracellular sig-
naling pathway, the CD271 receptor is cleaved twice, first by ADAM10/17 and
then by γ-secretase. This yields an intracellular signaling domain (p75-ICD),
which is thought to directly regulate transcription [175, 174, 176]. Considering
these versatile functions, it is not surprising that CD271 has been implicated
in various human pathologies like Alzheimer, Schizophrenia, Asthma [170] as
well as in melanoma brain-metastasis [177] and invasion [147, 178]. However,
the exact functional contribution of CD271 to these various effects remains to
be elucidated.
In sum, there is multiple evidence for common mechanisms underlying neural
crest delamination and melanoma metastasis. However, to what extend MSCs
and neural crest migratory pathways are involved in the metastatic process
remains to be determined.
Model systems to study melanoma metastasis
Considering the multiple evidence for common mechanisms underlying neural
crest delamination and melanoma metastasis, their experimental validation
might yield novel insights into the mechanisms driving melanoma dissemina-
tion. However, to investigate the functional contribution of neural crest EMT
pathways on melanoma progression, novel experimental model systems need
to be established first. This is particularly relevant considering the crucial con-
tributions of the microenvironment to the metastatic process [66, 70, 48](see
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section ’Metastatic disease’). As a consequence, the development of fully hu-
manized orthotopic systems has been deemed crucial, because such systems
would allow the investigation of central processes of human melanoma forma-
tion in their original tissue context [70, 103, 53]. However, for melanoma this
is technically challenging. Whereas orthotopic in-vitro model systems have
emerged using organotypic skin reconstructs [179, 180, 181, 182, 183, 184],
fully orthotopic, humanized in-vivo models are still missing. As such nei-
ther subcutaneous injection into immunocompromised mice [50, 49, 135] nor
more recent advances, including intradermal injections into human foreskin
grafts [107, 185] or skin reconstructs using human devitalized dermal sub-
strate [125], provide the structural context equivalent to the site of human
tumor formation. On the one hand, subcutaneous or intradermal injections,
even into a human skin graft [107, 185], cannot recapitulate the important
early steps of invasion from the epidermal compartment through the basement
membrane into the dermis. On the other hand, the use of a de-vitalized der-
mal substrate [125] creates an unfavorable chimeric environment, as the graft
gets populated with recipient fibroblasts rather than with human stromal cells
[103, 186, 187, 188, 189]. Thus, in order to recapitulate human melanoma pro-
gression in a humanized environment in-vivo, entirely new approaches have to
be developed.
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The overall aim of this thesis was to investigate the aggressive nature of mela-
noma with respect to its developmental origin, the neural crest. Along this line
the goal was to establish a potential link between MSCs, known neural crest
EMT signaling pathways, and the metastatic process. However, lacking an ap-
propriate model systems to study melanoma progression in an autochthonous
environment in-vivo, a humanized model system recapitulating all steps of
melanoma progression had to be established first. Based on this dichotomous
approach, the scope of this thesis comprised two major parts:
1. Development of a fully orthotopic, humanized in-vivo model for mela-
noma progression
2. Investigate the role of MSCs and neural crest EMT pathways in mela-
noma progression on the basis of the developed model
Part 1. In order to place human melanoma cells into their orthotpic en-
vironment at the dermis-epidermis boarder, we took advantage of recently
established human dermo-epidermal skin substitutes. Upon transplantation
onto the back of immuno-compromized rats, these substitutes mature into skin
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grafts closely resembling the human skin architecture. Using this approach we
explored the possibility to engineer melanoma progression in humanized skin
grafts.
Part 2. By establishing standard flow-cytometric isolation protocols, different
in-vivo models, retroviral over-expression and knock-down systems, as well as
immunohistochemical analysis, this project established the experimental basis
to address the role of MSCs and EMT pathways in melanoma progression.
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Melanoma development in engineered human skin substitutes
Aiming at the orthotopic positioning of human melanoma cells into an epi-
dermal stratum basale of human origin, we took advantage of human dermo-
epidermal skin substitutes [190, 191] (Figure 19). These substitutes were en-
gineered from freshly isolated human keratinocytes that were plated onto high
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Figure 19. Experimental approach. Scheme illustrating the experimental
approach using human organotypic skin substitutes as the basis for a human-
ized in-vivo melanoma model. The two main components, keratinocytes and
dermal fibroblasts, are enzymatically isolated from human neonatal foreskin
samples. A two step approach, during which the isolated keratinocytes are
seeded onto high density type-I collagen hydrogels containing human dermal
fibroblasts, allows the engineering of a human dermo-epidermal skin equiva-
lent suitable for transplantation. Addition of human melanocytes or melanoma
cells results in their orthotopic incorporation into the skin composites.
density type-I collagen hydrogels containing primary human dermal fibrob-
lasts. In such composites, melanocytes have been shown to incorporate into
their orthotopic location in-vitro [182]. To assess their incorporation in-vivo
we transplanted dermo-epidermal skin substitutes into full thickness wounds
on the back of immuno-compromized rats [190, 191] (Figure 20a), potentially
allowing to create tumors with extensions closely representing those of pa-
tients’ tumors. Using polypropylene rings to shelter the grafts from the sur-
rounding rat skin prevented wound healing through recipient-derived cells and
resulted in the maturation of the skin substitutes to a state macroscopically
resembling human skin (Figure 20b). The epidermal compartment revealed
normal stratification (Figure 20c) and a laminin-10 (Lam10)-positive basement
membrane tightly anchoring the cytokeratin-10 (K10)-expressing epidermis to
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the dermal compartment (Figure 20d). Staining of the skin grafts for the rat-
specific endothelial marker CD31 (rCD31) revealed a fully vascularized dermal
compartment indicating good acceptance of the graft (Figure 20e). The in-
tegrity of the humanized dermal compartment (Figure 20e, white dotted line),
marked by the human fibroblast-specific antibody CD90 (Thy1) (hCD90), was
maintained for at least 12 weeks, the latest time point analyzed. Moreover,
Ki67-positive proliferating cells in the stratum basale, in conjunction with
the expression of the wound-specific cytokeratin 16 (K16), indicated sustained
homeostasis of the epidermal tissue (Figure 20f). Importantly, the addition
of human melanocytes resulted in their recruitment to the stratum basale
(Figure 20g) where they fully differentiated into dendritic pigment-producing
melanocytes (Figure 20h).
Given the functional integration of melanocytes into their physiological sur-
roundings, we sought to determine the behavior of human melanoma cells
in this experimental set-up (for detailed information about all samples used,
see Table S1). To this end, we replaced the melanocyte fraction with human
melanoma cells expressing green fluorescent protein (GFP). Six weeks after
transplantation multiple large tumors pushing through an otherwise well de-
veloped epidermis were observed (Figure 20i). Macroscopically, these tumors
showed partial pigmentation (Figure 20i, black arrowhead) and a prominent
vasculature that readily ruptured upon touching, leading to excessive bleeding
(Figure 20i, white arrowhead). Macroscopic GFP expression confirmed that
the tumors originated from the seeded melanoma cells (Figure 20j). Histologi-
cal analyses further revealed large, densely growing, non-necrotic GFP-positive
tumors, expressing the two commonly used melanoma markers MelanA and
S100 (Figure 20k-n).
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Figure 20. Transplantation of
human skin substitutes con-
taining either melanocytes or
melanoma cells. Transplantation
of a human dermo-epidermal skin
substitute (a) drives its matura-
tion within 3 weeks (b). Scale
bar, 1cm. Analysis of the result-
ing skin by (c) H/E, (d) Lam10 and
K10, (e) hCD90 and rCD31, and
(f) Ki67 and K16 stainings reveals
typical skin histology and sustained
homeostasis. Scale bars, 50µm.
(g) Addition of human melanocytes
(HMB45) results in their ortho-
topic incorporation into the stra-
tum basale contacting the underly-
ing basement membrane (Lam5) in-
vivo. (h) This leads to fully differ-
entiated dendritic, pigment produc-
ing melanocytes (Fontana-Masson).
Scale bars, 20µmm. (i and j) Re-
placing the melanocytes with GFP-
expressing human melanoma cells
(ID4286) results in ulcerated, bleed-
ing (white arrowhead), partially pig-
mented (black arrowhead), GFP-
expressing tumors. Scale bars, 1cm.
(k-n) Analysis reveals a dense lesion
uniformly expressing GFP, MelanA
and S100. Scale bars, 1mm.
In vivo reconstituted melanoma
In vivo reconstituted Skin
a
H/Ec
hCD90 / rCD31e
HMB45 / Lam5g
b
K10 / Lam10d
Ki67 / K16f
Fontana-Massonh
GFPj
GFP / DAPIl
S100n
i
H/Ek
MelanAm
62
Published results
Engineering human melanoma progression in-vivo
To analyze the steps of melanoma progression, we added human GFP-expressing
primary melanoma cells in the physiological ratio of melanocytes to keratino-
cytes into the skin substitutes. Following tumor development over 42 days
in-vivo revealed the typical stages of melanoma progression (Figure 21a-c). At
the day of transplantation, the tumor cells were already uniformly integrated
into the thin epidermis (Figure 21a). Importantly, the in vitro generated skin
substitute did not reveal any melanoma cells in the dermal compartment (Fig-
ure 21a). This was crucial to our model, as inclusion of tumor cells into the
dermis would have compromised the experimental set-up, in which dermal tu-
mor growth needs to be established as a part of disease progression. 28 days
after transplantation, the graft was fully integrated and epidermal maturation
became evident by the appearance of distinct keratinocyte layers (Figure 21b,
middle panel). At this time point, the tumor cells had integrated into their
natural surrounding in the basal layer of the epidermis, where the presence
of melanomas in situ already marked the onset of radial, lentiginous tumor
growth (Figure 21b, right panel). After 42 days, tumor cell nests had become
vascularized (Figure 21c, arrowheads) and progressed to invasive tumors dis-
integrating the epidermis and penetrating the dermis (Figure 21c, middle and
right panel). Histopathologically, the resulting reconstituted tumors showed
strong resemblance to the original patient tumor from which the cells had been
derived (Figure 21d,e). Although the reconstituted tumor was smaller at the
time point analyzed, both lesions showed a similar nodular growth pattern
featuring lentiginous nests, a similar overall cell morphology, epithelial spread
of single cells (Figure 21d,e, insets 1) and dermal invasion (Figure 21d,e, insets
2). Strikingly, both parental and reconstituted tumors substantially interfer-
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Caption Figure 21. Human melanoma induction and progression
in engineered skin substitutes in-vivo. (a-c) Growth kinetics of GFP-
expressing human primary melanoma cells (ID12741) upon transplantation.
The left panels show the macroscopic maturation of the transplants while the
middle and left panels show a magnified view of consecutive H/E and GFP
stained transversal sections (e, epidermis; d, dermis). Scale bars, 100µm.
(d,e) Histological comparison of the reconstituted tumor (ID12741) and the
corresponding primary patient tumor (ID12741). Apart from the differences
in size, both lesions show a similar nodular growth pattern featuring lentigi-
nous nests and epithelial spread of single cells (insets 1), dermal invasion and
ulceration (insets 2), vascularization and a similar overall cell morphology.
Overview scale bars, 1mm, insets scale bars, 100µm.
ed with the epidermal integrity (Figure 21d and e), which presumably corre-
lated with ulceration, a clinically significant prognostic feature [192]. These
data demonstrate that reconstitution of a primary melanoma in a human-
ized environment not only recapitulates the onset of human disease in-vivo,
but also gives rise to tumors histologically resembling their original human
counterparts.
However, while primary melanoma biopsies are rarely accessible, a plethora of
metastasis samples and cell lines are available for research. Therefore, we ex-
plored the potential of cells derived from human metastasis samples to assume
primary tumor characteristics if exposed to the appropriate microenvironment.
Intriguingly, metastasis-derived melanoma cells recapitulated the key events of
early disease progression, indicating a remarkable context dependent plasticity
[193, 71]. Strikingly, cells derived from an axillary skin metastasis not only
adopted a progression pattern similar to transplanted primary melanoma cells,
but were also found to recapitulate many histopathological characteristics of
the primary patient tumor, from which the metastasis had originated (Figure
22a,b and Figure S1). Tumor growth started at the dermo-epidermal junction
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Figure 22. Reconstitution of a primary melanoma from an axillary
skin metastasis sample. (a) Patient-matched primary tumor (ID11928)
that gave rise to the metastasis used for reconstitution. (b) Tumor reconsti-
tuted from cells originally isolated from the corresponding axillary skin metas-
tasis (ID4286). The resulting tumors show identical growth characteristics as
the original primary tumor (insets). Note the barrier presented by the distinct
human-rat tissue border (dotted lines) restricting tumor growth to the human-
ized dermal compartment. (c) Matched subcutaneous xenograft (ID4286) in a
Swiss nude mouse. Subcutaneous inoculation results in highly necrotic (inset
1), encapsulated tumors growing in the subdermal fat tissue without epithelial
involvement (inset 2). Dotted line, border between murine skin and subdermal
fat tissue. Overview scale bars, 1mm, inset scale bars, 100µm.
giving rise to tumors mirroring the original tumor cell morphology, nodular
growth pattern, ulceration, as well as dermal and epidermal invasion (Figure
22a,b, insets 1). Furthermore, 50% of all reconstituted tumors (6/12) derived
from this axillary skin metastasis sample gave rise to satellite metastases in the
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skin, similar to those found in the corresponding primary tumor (Figure 22a,b,
insets 2 and Figure S1, inset 2). Intriguingly, these features were recapitulated
irrespective of whether the cells had been maintained as xenografts in mice
(Figure 22b) or as sphere cultures in vitro (Figure S1). Moreover, analysis of
the most commonly used clinical melanoma markers S100, MelanA, HMB45,
as well as the clinically relevant prognostic factor Ki67 [111] further confirmed
the close resemblance between reconstituted tumors and their patient-matched
counterparts (Figure S2). This showed that even melanoma cells isolated from
metastases harbor the potential to recapitulate original primary tumor growth
if placed in the appropriate tissue context.
Subcutaneous xenotransplantation into immunocompromized mice represents
the most widely used method for the analysis of human melanoma forma-
tion [194, 103]. Therefore, we compared the histology of the reconstituted
tumor (Figure 22b) to a matched subcutaneous xenograft (Figure 22c), reveal-
ing an advantageous effect of the humanized environment on tumor growth.
Whereas the humanized model system (Figure 22b) allowed the generation of
large, non-necrotic lesions closely resembling human melanoma histopathol-
ogy (Figure 22a), subcutaneous inoculation resulted in highly necrotic tumors
that lacked any epidermal involvement (Figure 22c and Figure S3). Despite
the abundant vascularization (Figure S3d), higher magnification revealed only
a small rim of healthy (Figure 22c, inset 1), proliferating (Figure S3e) cells
on the periphery of the tumor facing necrotic areas inside the tumor (inset
2). This suggests that additional influences from the microenvironment are
required to sustain tumor growth and progression independent of the vascu-
lature. In addition, none of the reconstituted tumors (N=19 tumors derived
from 3 different patient samples), including their occasionally arising dermal
metastases, ever invaded the underlying rat tissue (Figure 22b and Figure S1,
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dotted lines). Taken together, this indicates a favorable effect of the engineered
human stroma on human melanoma cell growth and progression [187, 189],
highlighting the paramount importance of a fully humanized environment in
studying melanoma progression.
Vascularization and hypoxia in reconstituted melanoma
A crucial step during tumor progression and a promising target for drug devel-
opment is neoangiogenesis. A key-parameter guiding this process is hypoxia
resulting from the imbalance of oxygen supply and consumption in a growing
tumor mass [195, 196]. To validate the potential use of reconstituted melanoma
in studying neoangiogenesis, we immunohistochemically assessed vasculariza-
tion and hypoxia in reconstituted skin and tumors. The dermal compartment
of skin substitutes transplanted without melanoma cells displayed hypoxia
and vascularization similar to the dermis of normal skin (Figure 23a,b, ar-
rowheads). In contrast, in reconstituted melanoma samples, we observed a
correlation between pronounced hypoxia and tumor vessel ingrowth (Figure
23c-e). GFP-tracking of melanoma cells revealed that tumor vessels were pre-
dominantly host derived (data not shown), in agreement with previous reports
[51]. Both in an early stage patient sample and the reconstituted tumor after
25 days, blood vessel ingrowth was found along highly hypoxic regions (Figure
23c,d, arrowheads). This onset of hypoxia-guided blood vessel ingrowth most
likely set the basis for the subsequent rapid progression to the highly vascu-
larized, non-necrotic lesions observed after 42 days in-vivo (Figure 23e,f).
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Caption Figure 23. Vascularization and hypoxia in the reconstituted
tumors. (a,b) Immunohistochemical analysis of vascularization (CD31) and
the hypoxia-associated glucose transporter-1 (Glut) (arrowheads) in adjacent
histological sections of human skin and reconstituted dermal epidermal skin
substitute. (c,d) Comparison of an early stage patient sample (ID 16754) and
a reconstituted tumor (ID 4286) after 25 days indicates blood vessel ingrowth
along a highly hypoxic region (arrowheads). (e) After 42 days in-vivo the
reconstituted tumors (ID 4286) are highly vascularized and contain only few
small hypoxic regions. Scale bars, 100µm. (f) Overview over hypoxia and the
intricate capillary network observed in the reconstituted tumor after 42 days
in-vivo. Scale bars, 1mm.
Reconstituting the switch from radial to vertical growth in mela-
noma
As malignant disease remains the central challenge in melanoma therapy, we
further investigated the potential of the system to faithfully recapitulate the
early phases of human tumor progression. The first step towards malignant
disease is the switch from radial to vertical tumor growth. Radial growth
is restricted to the epidermal compartment, whereas vertical growth extends
through the basement membrane into the dermis. Thus, we analyzed the func-
tional integrity of the basement membrane in reconstituted tumors at different
progression stages (Figure 24a). Starting with an intact, fully functional base-
ment membrane, initial radial growth progressively reduced the underlying
basement membrane until complete loss ensued.
A key-event driving this malignant progression is thought to be a process remi-
niscent of epithelial-to-mesenchymal transition (EMT) that is associated with
the acquisition of an invasive, mesenchymal phenotype in epithelial tumor
cells [96]. Although not an epithelial tumor, human melanoma express E-
cadherin [197], the loss of which has been functionally implicated in EMT and
tumor cell dissemination in some tumor types [96]. This makes E-cadherin an
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Caption Figure 24. Reconstituting the switch from radial to verti-
cal growth in melanoma. (a) Staining for the basement membrane marker
Laminin-5 (Lam5) reveals successive degradation of the basement membrane
in a reconstituted melanoma (ID12741). The final loss of the basement mem-
brane marks the onset of vertical tumor growth. Scale bars, 100µm. (b-g)
Comparison of E-cadherin (E-cad) expression in progressing stages of human
primary (b-d) and reconstituted melanoma (e-g). (b) Radially growing hu-
man primary tumor (ID12826), (c,d) Vertically growing human primary tu-
mor (ID16754) with and without dermal infiltrates (DI). (e-g) Correspond-
ing stages of a reconstituted tumor using human primary melanoma cells
(ID12741). Arrowheads indicate cells negative for E-cadherin without contact
to their parental tumors. To visualize the tumor borders, the patient samples
were counterstained with S100 and the reconstituted tumors with GFP (RGP,
radial growth phase; VGP, vertical growth phase). Scale bars, 100µm
interesting candidate to investigate potential EMT-like processes underlying
melanoma cell dissemination. Therefore, we compared the expression pattern
of E-cadherin on histological samples of primary patient (N=4) and recon-
stituted melanoma (N=9 tumors derived from 3 different patient samples)
(Figure 24b-g). During the early stages of tumor development (radial growth
phase, RGP) none of the primary human tumors analyzed nor of the recon-
stituted tumors showed an overt downregulation of E-cadherin, which was
strongly expressed in epidermal lesions extending from the epidermis (Figure
24b and e). Strikingly, E-cadherin expression was even retained in bigger le-
sions showing distinct vertical growth phase (VGP) characteristics (Figure 24c
and f). In contrast, both in the reconstituted tumors and the patient samples,
substantial downregulation of E-cadherin was only observed in dermal tumor
cell infiltrates (DI) that had lost all contacts to the epidermis (Figure 24d and
g). In addition, in 12 out of 13 samples analyzed (N=4 patient samples and 9
reconstituted tumors), E-cadherin-negative cells were observed that appeared
to move away from the parental tumor (Figure 24b-g, arrowheads). Taken
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together, our data show that even complex events like dermal invasion, the in-
duction of neoangiogenesis, and early tumor cell dissemination were faithfully
recapitulated using our humanized melanoma reconstitution approach.
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Supplementary Figures
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Figure S 1. Reconstitution of a melanoma from an axillary skin
metastasis sample maintained as sphere culture. 25 days after trans-
plantation of the sphere culture-derived cells (ID 4286), typical pathological
features of aggressive melanoma start to be recapitulated. Mark tumor induc-
tion in the basal layer of the epidermis, dermal and epidermal invasion includ-
ing pagetoid spread (inset 1, arrowhead) and a developing satellite metastasis
(inset 2). Note the barrier presented by the distinct human-rat tissue border
(dotted lines). Overview scale bars, 1mm, inset scale bars, 100µm.
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Figure S 3. Analysis of a human melanoma subcutaneous xenograft.
(a) Tumor histology upon injection of the melanoma sample used in Figure
22 (ID4286) into the subcutaneous space of a Swiss nude mouse. (b) GFP
expression confirms that the tumors originated from the injected cells. (c)
Immunohistochemical analysis of the vasculature (CD31) and hypoxia (Glut).
(d) Although generally highly vascularized, the magnified view reveals that
the tumor cells are still subjected to highly hypoxic conditions. (e) Although
histologically (H/E) not resembling a human primary melanoma, the expres-
sion of the most commonly used melanoma markers Ki67, S100, MelanA and
HMB45 is retained (f) Double staining for E-cadherin and GFP shows overall
strong E-cadherin expression. Scale bars a-c, 1mm. Other scale bars, 100µm.
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The role of CD271 positive MSCs in tumor progression
CD271 expression in vivo
CD271 / GFP
CD271 / S100a
b
Figure 25. CD271 expression in a patient and reconstituted mel-
anoma. (a) Overview over a human primary melanoma sample stained for
CD271 and S100. Whereas only few tumor cells are positive for CD271, other
cell types like nerves and glia cells strongly express CD271. (b) CD271 stain-
ing in a reconstituted melanoma. Based on the GFP expression all tumor cells
can be easily identified. CD271 appears to be preferentially expressed at the
invasive front.
Following its experimental validation, we took advantage our newly developed
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model system to address the potential implication of CD271 positive neural
crest-like MSCs [107, 51] in tumor progression. Comparison of the CD271
expression pattern between a human primary tumor and a reconstituted mel-
anoma revealed the advantage of the system for functional analyses (Figure
25). Different from the patient sample (Figure 25a), all tumor cells in the
reconstituted sample could be unequivocally visualized based on their expres-
sion of GFP (Figure 25b). The importance of this became clear following the
immunohistochemical analysis of CD271 expression on a histological patient
section (Figure 25a). Although counterstained with the melanoma marker
S100, in some cases it was impossible to differentiate between tumor cells and
other structures positive for CD271 like nerves, glia cells and potentially oth-
ers. Taken together with the possibility that not all tumor cells necessarily
express S100, this approach did not allow any conclusion with regard to the
abundance and location of CD271 positive tumor cells in patient samples.
In contrast, immunohistochemical analysis of a reconstituted tumor counter-
stained with GFP allowed a precise analysis of the CD271 expression pattern
in all tumor cells, including single cells dispersed in the dermal compartment
(Figure 25b). Based on this approach, CD271 expression was found to be
preferentially located at the invasive front indicating a potential implication
of neural crest-like melanoma cells in the invasive process.
Tumor initiating potential of CD271 positive melanoma cells in-vivo
To assess whether these invasive CD271 positive cells showed properties of
MSCs, we fractionated a subcutaneous xenograft on the basis of CD271 us-
ing fluorescent activated cell sorting (FACS) (Figure 26a). Following the
transplantation of dermo-epidermal skin substitutes containing either 50’000
CD271Pos, CD271Neg or unsorted control cells, tumor growth was assessed
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Figure 26. Transplantation of CD271 sorted cells. (a) Human CD271-
positive and CD271-negative melanoma cells were isolated from a subcuta-
neous xenograft by FACS. The unsorted cells served as control. (b) 42 days
after transplantation all fractions gave rise to macroscopic tumors. The strong
GFP expression proves that all tumors were derived from the transplanted
cells. The indicated animal succumbed to an infection 4 weeks after trans-
plantation.
after 42 days in-vivo (Figure 26b). Surprisingly, in contrast to previously
published results [107, 51], all fractions gave rise to macroscopic, ulcerated
tumors (Fig. 26b, the indicated animal died of an infection, but also revealed
tumor growth upon histological analysis (data not shown)). In support of the
reports questioning CD271 as a genuine MSC marker [49, 50], this showed
that also in a humanized environment CD271 expression does not correlate
with an exclusive tumor induction potential.
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Figure 27. CD271/Sox10 double staining in CD271-sorted samples
Double staining for CD271 and Sox10 on reconstituted tumors induced by
CD271-positive, CD271-negative and unsorted human melanoma cells reveals
that all samples contain double positive cells. Correlation to the GFP-positive
tumor cells excludes a potential contamination from infiltrating cell types.
However, considering the growing body of evidence that tumor stem cells rep-
resent plastic entities [66, 48, 71], we addressed the question whether also
CD271 positive cells could arise as a consequence of tumor cell plasticity. In-
triguingly, in support of this theory, immunohistochemical analysis revealed
that all tumors, independent of the fraction they originated from, contained
cells positive for the MSC-associated NCSC marker CD271 and Sox10 [51]
(Figure 27).
Intrigued by this finding, we developed a novel time-lapse imaging technique
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to address whether MSCs can be dynamically regulated (Figure 28). To this
end we created a migration assay that retained the cellular integrity and imme-
diate microenvironment of the cells prior to their emigration by using whole
BF
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1
0h 50h 100h
a
b
Figure 28. Tumor emigration model. (a) Schematic overview of the ex-
perimental approach. Approximately 1mm3 large tumor pieces are microdis-
sected from a subcutaneous xenograft. Coating with Fibronectin and Matrigel
provides the structural stability for the tumor pieces to adhere to a cell culture
dish. Following incubation in serum containing growth medium tumor cells
start to emigrate in the range of 4-6 days. (b) Using an automated micro-
scope equipped with an incubation chamber allows to image the emigrating
cells. Tumor cells can be differentiated from emigrating mesenchymal cells
by their fluorescent tag. Adding a fluorochrome-coupled CD271 antibody al-
lows to follow CD271 expression on emigration tumor cells with high temporal
resolution.
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tumor pieces (Figure 28a). This was achieved by microdissecting approxi-
mately 1mm3 large pieces of a GFP expressing subcutaneous xenografts and
plating them into a cell culture dish. Coating with Fibronectin and Matrigel
provided the structural stability for the pieces to adhere to the dishes. Incu-
bation at 37◦C in serum containing growth medium resulted in the emigration
of tumor cells in the range of 4-6 days. In combination with an automated
microscopy system equipped with an incubation chamber set to 5 minutes pic-
ture intervals, this approach allowed us to follow emigrating cells with high
temporal resolution. Furthermore, addition of a directly fluorochrome-coupled
anti-CD271 antibody into the growth medium enabled us to follow expression
of CD271 in emigrating tumor cells (Figure 28b). Thus, based on this system
potential dynamic changes in CD271 expression were assessed by imaging in-
dividual cells at high magnification (Figure 29). Interestingly, this revealed
that some emigrating tumor cells indeed showed the ability to become CD271
positive over a time range of 600 minutes (Fig. 29a). Moreover, after 6 days
in culture the CD271 expressing cells were located mainly at the outer pe-
riphery of the emigrated cells (Fig. 29b). These findings demonstrated that
a dynamic regulation of CD271 in melanoma cells can occur, which provided
the first experimental evidence for a potential plasticity inherent to migrating
melanoma cells. However, whether the acquired expression of CD271 really
reflected an acquired stem cell potential could not be determined using this
approach.
The functional role of CD271 in-vivo
Thus, to address the functional role of CD271 in melanoma progression, a
lentiviral overexpression system was constructed (Figure 30a). To allow the
unequivocal identification of infected cells in all subsequent analyses, a system
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Figure 29. CD271 expression in emigrating melanoma cells. (a)
Imaging cell emigration at 20x magnification reveals that some tumor cells are
able to induce CD271 expression over a time range of 600 minutes (arrows).
(b) Overview over the emigrated cells after 6 days. CD271 positive cells are
mainly located at the outermost boarder.
concomitantly expressing GFP from an internal ribosome entry site (IRES)
was chosen. Infection of human melanoma cells with this construct resulted
in a high efficiency of approximately 90% and a more than 2-fold upregulation
of CD271 expression after 5 days in culture (Figure 12b).
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Figure 30. Lentiviral CD271 overexpression. (a) Lentiviral overexpres-
sion vector used in this study. Using an internal ribosome entry site (IRES)
allows the concomitant expression of CD271 and GFP. (b). Flow cytometric
analysis reveals CD271 expression to be induced by more than 2-fold in human
melanoma cells 5 days after infection.
Based on this lentivrial vector, we subsequently addressed the effect of CD271
overexpression on tumor growth and progression in-vivo. To this end cells over-
expressing CD271 and cells containing the empty control vector were seeded
into skin substitutes (N=2 animals per group). However, histological analy-
sis revealed no striking difference with respect to tumor size and morphology
after 42 days in-vivo (Figure 31). But interestingly, while this questioned
the functional implication of CD271 overexpression in tumor induction and
growth, a striking effect with respect to the metastatic potential was observed
(Figure 31). Comparison of several section throughout the control (Figure
31a) and CD271 overexpressing tumors (Figure 31b) indicated an enhanced
ability to form satellite metastases in the sub-dermal rat tissue in response
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Figure 31. CD271 overexpression in-vivo. (a) Transplantation of cells
carrying an empty control vector gives rise to large, invasive tumors that are
mostly confined to the humanized dermal compartment. (b) Although similar
in size and morphology, cells overexpressing CD271 give rise to tumors with
an enhanced proclivity to seed multiple satellite metastases in the subdermal
rat tissue. Scale bars, 1mm.
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to CD271 overexpression. This is of particular interest considering that sub-
dermal metastases have not been observed in this model system before (see
section ’Engineering melanoma progression in a humanized environment in-
vivo’), which suggested an increased ability of CD271 expressing cells to adapt
to a hostile microenvironment. To exclude that the similar growth rate of
the primary tumors were induced by a downregulation of ectopic CD271 ex-
pression in-vivo, we immunohistochemically assessed the CD271 expression
pattern on whole transversal sections (Figure 32). As expected, the tumors
arising from the control cells only revealed a moderate amount of CD271 ex-
pression (Figure 32a). The only exception constituted a small population of
scattered cells showing strong invasive growth (Figure 32a, inset). Surpris-
ingly, although showing uniform GFP expression, not all tumors carrying the
overexpression vector also revealed detectable CD271 expression (Figure 32b).
But the underlying reason for this remains to be addressed. Along this line
the used construct or cell intrinsic or extrinsic regulatory mechanism could
offer conceivable explanations. Nevertheless, already the fact that in the same
graft no differences in tumor size with respect to CD271 levels were observed
excluded a direct effect of CD271 expression on tumor induction and growth.
But importantly, CD271 expression was detected in the sub-dermal metastasis
as well as in a strongly invasive population of cells (Figure 32b, inset). Taken
together, these findings indicate that primary tumor growth is not directly
affected by the level of CD271 expression in human melanoma cells. However,
strong expression on the dermal metastasis and on highly invasive cells in the
control points to a potential implication of CD271 positive cells in invasion
in-vivo.
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Figure 32. Analysis of CD271 overexpression levels in-vivo. (a)
Analysis of CD271/GFP expression in a control tumor carrying an empty
vector. Whereas the large tumors only contain few cells positive for CD271,
a strong increase is observed in a small population of highly invasive cells
(inset). (b) Despite positive for GFP, not all tumors derived from CD271
overexpressing cells reveal detectable CD271 levels. Strong expression is found
in some primary tumors, the sub-dermal metastasis as well as some single,
invasive cells.
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Figure 33. Lentiviral E-cadherin knock-down. (a) Lentiviral knock-
down vector used in this study. Ablation is achieved by expressing E-cadherin
shRNA from a constitutive active hU6 promoter. Red fluorescent protein
(RFP) is expressed from an independent promoter and serves as fluorescent
marker. As a control the same vector carrying a scrambled shRNA sequence
was used. (b) Flow cytometric analysis shows a 2-fold reduction of E-cadherin
levels in human melanoma cells 5 days after infection. (c) CD271 expression
is not altered upon E-Cadherin ablation.
Analysis of E-cadherin knock-down in-vivo
Given the potential implication of CD271 positive cells in invasion and the
dynamic regulation of CD271 expression in emigrating melanoma cells, we ad-
dressed the possibility that invasive CD271 positive cells arise as a consequence
of an EMT process. Based on the findings implicating the loss of E-cadherin,
the main determinant of EMT in epithelial carcinomas [160], in melanoma
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invasion (Figure 24), we addressed to what extend loss of E-cadherin might be
involved in inducing MSC features in human melanoma cells. To this end we
constructed a shRNA-based lentiviral E-cadherin knock-down vector. To dif-
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Figure 34. E-cadherin knock-down in-vivo. (a) Skin graft containing E-
cadherin knock-down cells after 35 days in-vivo. Given the lack of macroscopic
tumor growth, analysis was based on the histological evaluation of 5 indepen-
dent positions throughout the sample. (b) Representative pictures of 3 of the
5 analyzed positions of a control (scr shRNA) and E-cadherin knock-down
(E-cad shRNA) sample. Compared to the control, loss of E-cadherin results
in loose cell aggregates missing any higher structure. Scale bars, 50µm.
ferentiate between between infected cells and non-infected cells, a fluorescent
marker was introduced by replacing the antibiotic resistance with Red Flu-
orescent Protein (RFP) driven from an independent promoter (Figure 33a).
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As a control vector the same construct carrying a scrambled shRNA sequence
was used. Infection of human melanoma cells resulted in an approximately 2-
fold reduction of E-cadherin expression within 5 days (Figure 33b). However,
contradicting a direct relationship between loss of E-cadherin and induction
of MSC features, ablation of E-cadherin was not found to induce CD271 ex-
pression in-vitro (Figure 33c). But considering that there is no direct evidence
proving that the loss of E-cadherin is an underlying cause of melanoma inva-
sion, the relevance of this finding was unclear. Thus, we embarked to determine
whether loss of E-cadherin is a causative factor of melanoma progression or
only a result thereof. To address this question we transplanted skin substitutes
containing melanoma cells carrying either the E-cadherin knock-down or the
scrambled control vector (Figure 34) (N=2 animals per group). Because no
macroscopic tumor growth was observed after 35 days in in-vivo, each sample
was histologically analyzed at 5 independent positions (Figure 34a). Repre-
sentative pictures of 3 of these 5 positions are shown in Figure 34, 35 and 36.
Intriguingly, in comparison to the control sample loss of E-cadherin revealed
a striking effect on tumor shape in-vivo. Whereas the control cells were found
to form dense, coherent tumors, loss of E-cadherin resulted in loose aggre-
gates of cells missing any discernible structure (Figure 34b). Furthermore,
detailed analysis of E-cadherin and CD271 expression on adjacent histological
sections revealed a correlation between loss of E-cadherin, CD271 expression,
and disseminated single cells. Strikingly, although E-cadherin expression was
generally weak in the control sample, expression of CD271 and E-cadherin
was found to be mutually exclusive (Figure 35). Whereas this effect was not
so prominent in the big lesion analyzed, it became significant in the dermal
parts of two tumors where the expression of CD271 was drastically upregu-
lated in single, E-cadherin negative cells moving away from the primary tumor
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Figure 35. Analysis scrambled shRNA control in-vivo. Immunohisto-
chemical analysis of CD271 and E-cadherin expression on consecutive sections
at 3 independent positions. (a) Despite weak in this big lesion, E-cadherin ex-
pression does not overlap with CD271 expression. (b,c) CD271 expression be-
comes progressively stronger in single, E-cadherin negative cells moving away
from their primary tumor. Scale bars, 100µm.
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Figure 36. Analysis of E-cadherin knock-down in-vivo. Immunohisto-
chemical analysis of CD271 and E-cadherin expression on consecutive sections
at 3 independent positions. (a) Although almost entirely positive for CD271,
expression is weaker in this more dense aggregate of tumor cells. (b,c) In
the invasive, more scattered cell aggregates CD271 is ubiquitously expressed.
Scale bars, 100µm.
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(Figure 35b,c). Interestingly, this effect became even more prominent in the
tumors lacking E-cadherin expression (Figure 36). Although weak in a larger
aggregate of cells (Figure 36a), the smaller, more scattered lesion induced by
E-cadherin ablation showed a strong, uniform expression of CD271 (Figure
36b,c). Taken together, these results provide the first direct evidence that the
loss of E-cadherin can act as a determinant of melanoma invasion in-vivo. Fur-
thermore, considering the preliminary findings that invasive melanoma cells
appear to upregulate the MSC-associated marker CD271, these results present
a promising start for future projects.
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Melanoma reconstitution model
Isolation of human skin cells
This study was conducted according to the Declaration of Helsinki Principles.
Human foreskin samples were obtained from patients after permission by the
ethic commission of the Canton Zurich and after informed consent given by
parents or patients. Keratinocytes and fibroblasts were isolated as described
previously [190, 191]. In brief, human foreskin samples were digested in 12
U/ml dispase in Hank’s buffered salt solution containing 5 µg/ml gentamycin
overnight at 4 ◦C. This allowed the subsequent separation of the epidermis
and dermis using forceps. In order to isolate the desired cell types from the
respective compartments, the dermis and epidermis were separately processed
after separation. To isolate keratinocytes or melanocytes the epidermis was
further digested in 1% trypsin, 5 mM EDTA for 5 minutes at 37 ◦C and
the digested epidermal cells were cultured in serum-free keratinocyte medium
containing 25 µg/ml bovine pituitary extract, 0.2 ng/ml EGF, and 5 µg/ml
gentamycin or in melanocyte growth medium containing 1 ng/ml bFGF, 10
ng/ml PMA, 5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 2 ml bovine pitu-
itary extract (all from PromoCell) and 5 µg/ml gentamycin, respectively. To
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establish primary dermal fibroblast cultures the dermal tissue was digested in
2 mg/ml collagenase for 60 minutes at 37 ◦C followed by culturing in DMEM
supplemented with 10% fetal calf serum, 4 mM L-alanyl-L-glutamine, 1 mM
sodium pyruvate, and 5 µg/ml gentamycin. Collagenase was from Sigma, all
other compounds were from Invitrogen.
Construction of human organotypic skin cultures
Organotypic cultures were prepared using a previously established transwell
system consisting of 6 well cell culture inserts containing a porous membrane
(3.0 µm pore-size, BD Falcon) [190, 191]. The membranes were covered with
collagen type I hydrogels containing human dermal fibroblasts prepared ac-
cording to the protocol of Costea et al. [198]. Briefly, 0.7 ml rat tail collagen
type I (3.2- 3.4 mg/ml, BD Biosciences), was added to 0.2 ml chilled neu-
tralization buffer containing 0.15 M NaOH and 1x105 fibroblasts. After poly-
merization (10 min at room temperature and 20 min at 37◦C) these dermal
equivalents were grown in DMEM supplemented with 10% FCS for 5 days.
Corresponding to the physiological ratio of melanocytes to keratinocytes (ap-
prox. 1:5), 5x104 melanocytes or melanoma cells were mixed with 2-2.5x105
keratinocytes and seeded onto each dermal equivalent. To avoid dispersion
the cells were pippeted into siliconized polypropylene rings of 5 mm diameter.
After 12 h the rings were removed, 1 ml keratinocyte/melanocyte medium
(ratio 5:1) was added in the upper chamber, and 2 ml was added to the lower
chamber. Culturing for 1 week with regular medium changes gave rise to the
dermo- epidermal skin substitues used for transplantation.
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Transplantation of human organotypic skin substitutes
The study protocol was approved by the local Committee for Experimental
Animal Research (permission number 135/2010). The surgical procedure was
performed as described previously [199, 190, 191]. In short, a fully thickness
skin defect was surgically created on the back of 10 weeks old, female athymic
Nu/Nu rats (Harlan, Netherlands). To prevent wound closure from the sur-
rounding skin, metal rings (27mm in diameter, made to order from stain-
less steel at the ETH Zurich) were sutured into the skin defects using non-
absorbable polyester sutures (Ethibond R©, Ethicon). The dermo-epidermal
skin substitutes were placed into the rings, fixed with 4-6 stiches, and cov-
ered with a silicone foil (Silon-SES, BMS). The rings were then covered with
5 cm x 5 cm polyurethane sponges (Ligasano R©, Ligamed) and medical strip.
Sedation and anesthesia was performed as follows. All animals were sedated
with 15mg/kg ketamine s.c. (Pfizer) prior to surgery. Anesthesia was induced
and maintained using isofluorane (Abbott), post-operative analgesia was pro-
vided by 0.5 mg/kg buprenorphine s.c. (Temgesic R©, Essex). Animals were
sacrificed at the indicated time points with carbon dioxide. The grafts were
excised and prepared for immunohistchemical processing.
Tumor cell isolation and xenograft inoculation
All patients enrolled in the study were treated at the Dermatology Depart-
ment of the University Hospital of Zurich. The biobank project including
the establishment of cell cultures was approved by the local IRB (EK647 and
EK800) (ethics committee of canton Zurich) and all patients gave written in-
formed consent. The patient samples used for transplantation were derived
from one primary tumor and two metastases (see Supplementary Table S1).
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After surgical resection, the solid, metastatic lesions were immediately dis-
sociated into single-cell suspensions using HBSS (without Ca2+ and Mg2+,
Invitrogen) containing Collagenase III (1mg/ml, Worthington Bioch.) and
Dispase (0.5 mg/ml, Roche) [200]. Incubation for 1h at 37◦C with concurrent
mincing allowed for complete digestion. The resulting cell suspension was
filtered through a 40 µm nylon mesh and single cells were harvested and re-
suspended in 200µl Matrigel matrix (BD Biosciences) 1:1 diluted with RPMI-
1640 (Invitrogen). Subcutaneous (s.c) injections using a 1- ml syringe with a
25-gauge hypodermic needle in the flank of BALB/c-Swiss nude (CAnN.Cg-
Foxn1nu/Crl, Harlan) mice established the initial xenograft cultures, which
were maintained using the same routine for re-injection.
GFP infection
The GFP-expressing lentivirus was produced as described [201]. Lentivirus-
containing supernatants were collected 48 hours after transfection, filtered
through a 0.22 µm membrane and transferred to target cells freshly iso-
lated from mouse xenografts. During transfection cells were maintained under
sphere conditions as described below. After one week the cells were reinjected
s.c. into Swiss nude mice. The resulting tumors were dissociated as described
above and the GFP-positive cells were purified by FACS-sorting. Re-injection
resulted in purified GFP-positive xenografts. For all further passages GFP-
expression was regularly analyzed by FACS and, if deemed necessary, purified
again.
Cell culture
Melanoma cells in vitro were maintained in sphere cultures as previously de-
scribed for neural stem cells [202]. Briefly, single cells were plated in flasks
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(Nunc) coated with Poly(2-hydroxyethylmethacrylate) (Poly- Hema, Sigma)
at a density of 20,000 viable cells/ml in DMEM-F12 1:1 media (Gibco) contain-
ing 1x B-27 supplement (Invitrogen), 20 ng/ml FGF2 (PeproTech), 10 ng/ml
EGF (PeproTech), 5% Pen/Strep (Invitrogen). The resulting spheres were
collected after 7-10 days by gentle centrifugation (800 rpm), dissociated using
PBS containing 2 mM EDTA and replated into Poly- Hema coated culture
flasks. Passage three sphere cells were used for transplantation.
Immunohistochemistry
All tissue used for immunohistochemistry was fixed in 4% paraformaldehyde
and embedded in parafin. Sections were deparaffinized in xylene and rehy-
drated. Epitope retrieval was performed in Tris-EDTA pH9 for Glut1, in Tris
pH6 for Ki67 and S100, and with proteinase K for CD31. Staining was per-
formed using the according Dako REAL kit 5005 with the following primary
antibodies at the indicated dilutions: Melan-A (clone A103, 1:60, Novacas-
tra), CD31 (clone JC70A, 1:40, Dako), Glut-1 (AB1341, 1:1000, Chemicon),
S100 (L-S100P, 1:200, Novacastra). Melanin was visualized using the Masson-
Fontana technique with nuclear fast red as counterstain (Eichhoff et al., 2010).
Immunofluorescence
Immunofluorescence was performed on either cryo or parafin sections. For
cryo processing tissue samples were embedded in OCT compound (Sakura
Finetek/Digitana AG) and frozen at -20◦C. Cryosections were fixed and per-
meabilized in acetone for 5 min at -20◦C, air dried, washed 3x in PBS and
blocked in PBS containing 2% BSA (Sigma) for 30 minutes. Following pri-
mary antibodies were incubation in blocking buffer for 1 hour at room tem-
perature : K10 (clone DE-K10, 1:100, Dako), laminin 10 (clone 4C7, 1:25,
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Dako), human melanosome (clone HMB45, 1:50, Dako), K16 (clone LL025,
1:100, Millipore), Ki-67 (clone B56, 1:200, BD Pharmingen), anti-rat CD31
(PCAM-1, clone TDL-3A12, 1:50, BD Pharmingen), laminin 5 (clone P3H9-2,
1:100, Labforce), human fibroblasts (clone AS02, anti-CD90 (Thy-1), 1:100,
Dianova). After washing the sections were incubated with FITC-conjugated
goat anti-mouse (Dako) secondary antibodies for 1h at room temperature.
Parafin sections were deparaifinized as described above. Antigen-retrieval was
performed in 10 mM trisodium citrate buffer at pH 6.0 and a Microwave Histo-
processor (Milestone). Sections were incubated over-night at 4◦C with the
following primary antiobodies: MelanA (clone A103, 1:100, Abcam), S100P
(Z0311, 1:400, DAKO), human melanosome (clone HMB45, 1:100, DAKO),
E-cadherin (C20820, 1:200, Translab), GFP (ab290, 1:400, Abcam). Sections
were subsequently incubated with the according secondary antibody for 1 h
at room temperature: Cy2-conjugated goat anti-rabbit (1:250, Jackson Im-
munoResearch) or Alexa 546-conjugated goat anti-mouse (1:500, Invitrogen).
All slides were counterstained with Hoechst 33342 (Invitrogen).
Image acquistion
Microscopy pictures were taken using a Leica DMI6000 microscope equipped
with a fluorescent lamp, a high sensitivity black and white camera (Leica
DFC350 LX) for immunofluorescent images and a color camera (Leica DFC420c)
for immunohistochemistry images. All macroscopic tissue pictures were taken
using a Leica MZ16 stereo-loupe equipped with a fluorescence lamp. The his-
tological overview pictures were taken using a Zeiss Mirax Midi Slide Scanner.
Fluorescent overview pictures were taken using the tile scan function included
in the Leica DMI6000 microscope software.
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Patient samples
All patients enrolled in the study were treated at the Dermatology Department
of the University Hospital of Zurich. The biobank project including the estab-
lishment of cell cultures was approved by the local IRB (EK647 and EK800)
(ethics committee of canton Zurich) and all patients gave written informed
consent. Characteristics of the used biopsies are listed according to their
figure contribution: Fig. 25: (a) ID12826, F/94, primary, location unknown,
T1bN0M0 (b) ID4286, M/35, metastasis, skin axillary, pT4bN3M0; Fig. 26,27:
ID4286, M/35, metastasis, skin axillary, pT4bN3M0; Fig. 28: ID12741,M/80,
primary, upper right arm, T4bN2bM0; Fig. 29: ID2481, F/63, metastasis,
Lung, pTxN3M1c; Fig. 30-36: ID25126, F/76, metastasis, lymphnode left
groin, T3N3M1a.
Immunofluorescence
Immunofluorescence was performed on parafin sections. Sections were deparaf-
finized in xylene and rehydrated. For E-cadherin, Sox10 and S100 stainings
antigen-retrieval was performed with 10 mM trisodium citrate buffer at pH
6.0 in a Microwave Histoprocessor (Milestone). For CD271 staining antigen-
retrieval was performed with proteinase K for 10min at RT. Following antigen-
retrieval the section were incubated in blocking buffer consisting of PBS sup-
plemented with 10% goat serum and 0.2% Triton-X for 15min at RT. After
blocking, sections were incubated over-night at 4◦C with the following pri-
mary antibodies: E-cadherin (C20820, 1:200, Translab), GFP (ab290, 1:400,
Abcam), S100P (Z0311, 1:400, DAKO), CD271 (130-091-884, 1:100, Miltenyi
Biotec), Sox10 (MAB2864, 1:400, R&D). Sections were subsequently incu-
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bated with the according secondary antibody for 1 h at room temperature:
Cy2-conjugated goat anti-rabbit (1:250, Jackson ImmunoResearch) or Alexa
546-conjugated goat anti-mouse (1:500, Invitrogen). All slides were counter-
stained with Hoechst 33342 (Invitrogen). All pictures were taken on a Leica
DMI6000 microscope. Overviews were created from individual pictures using
the automated stitching function of Photoshop CS4 (Adobe).
Flow cytometry and FACS-sorting
Sorting and analysis were performed as described before [51]. In short, all steps
for flow cytometry were performed in DMEM supplemented with 10% FCS (In-
vitrogen), 1% Pen/Strep (Invitrogen) and 2mM EDTA. For sorting or analysis,
single cell tumor samples were stained with anti-human CD271 (1:100, FITC-
conjugated: 130-091-917, or APC-conjugated: 130-091-884, Miltenyi Biotec)
and anti-human E-Cadherin (1:100, APC-conjugated: 130-095-412, Miltenyi
Biotec) for 30min at 4◦C. Samples were measured with a FACScanto II (BD
Biosciences) an analyzed with Flowjo software. Sorting was performed with a
FACSAria (BD Biosciences).
Tumor emigration
Mice carrying subcutaneous, GFP expressing xenografts were sacrificed in CO2
and tumors were resected. Using micro-dissection tools 1mm3 large pieces
were dissected and washed in PBS. To achieve enough stability for the pieces
to adhere, the wells of a 48 well plate (NUNC) were coated with Fibronectin
(Sigma). Placing the tumor pieces into the coated wells, also the tumor pieces
themselves were coated with Fibronectin and incubated for 30min at 37◦C.
Following incubation, the pieces were additionally coated with cold Matrigel
(BD Biosciences) diluted 1:5 in DMEM medium (GIBCO) and again incubated
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for 30min at 37◦C. After incubation 1ml pre-warmed growth medium (DMEM
supplemented with 10%FCS and 1% P/S) was carefully added to each piece.
For the live imaging CD271 antibody (APC-conjugated: 130-091-884, Miltenyi
Biotec) was directly diluted 1:100 in the growth medium. Time-lapse imaging
was performed with a Leica DMI6000 microscope equipped with an incubation
chamber set to 5min picture intervals. Single pictures were combined to movies
using ImageJ.
Virus production
The GFP-expressing lentivirus was produced as described [201]. All other
constructs were produced by L. Habegger in the range of his master thesis.
Lentiviral particles were produced in HEK293T cells following calcium phos-
phate transfection. Supernatant was collected 3x every 12h, pooled and con-
centrated 100x using a Beckman Ti70 rotor at 25’200RPM. Cells were infected
in a final concentration of 20x under sphere conditions as described above. In-
fection efficiency was checked 5 days after infection using FACScanto II (BD
Biosciences) flow-cytometer.
In-vivo experiments
All experiments were performed as described above. Independent of the em-
ployed cell types, 50’000 cells were used for all tumor reconstitutions. For the
functional analyses, 2 animals per group (CD271 overexpression, CD271 con-
trol, E-cadherin shRNA, E-cadherin scrambled control) were transplanted. All
animals were sacrificed at the indicated time points using CO2, grafts were re-
sected, fixed in 4% Pfa, embedded in Parafin and analyzed as described above.
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Using human skin substitutes to model melanoma
progression in-vivo
Conclusion
By using human skin substitutes we were able to develop a fully humanized in-
vivo system faithfully recapitulating all initial steps of human melanoma pro-
gression. In one and the same system radial growth including pagetoid spread,
vertical growth, marker expression, angiogenesis, ulceration, and hypoxia were
validated in direct comparison to patient-matched tumor samples (Figure 19
- Figure 24). Interestingly, all these traits were re-established upon tumor re-
constitution with samples derived from both primary melanomas and the more
abundant metastases biopsies. This demonstrates the potential of cancer cells
to adapt to the local environment, making our system amenable to a wide
range of human melanoma samples. This concurs with recently described dy-
namic processes mediating tumor initiation and maintenance [72, 71]. Along
this line it will be interesting to assess how environmental cues override the
intrinsic differences between primary and metastatic tumor cells.
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Efficiency
A crucial point to consider for every model system is its efficiency and re-
producibility. Achieving an overall reconstitution efficiency of about 90% (17
tumors out of 19 transplantations using 3 individual patient samples), the
method described here provides a reliable and repeatable experimental set-up.
Importantly, irrespective of the cells’ origin or of previous expansion in-vivo or
in-vitro, the different samples did not exhibit any discernible differences with
respect to the key events of disease progression. This makes our model a valu-
able tool for pre-clinical drug testing in an experimental set-up reminiscent of
the patient situation. For in-vitro tumor cell expansion, we have purposely
employed melanomasphere cultures rather than adherent cell cultures. This
is because such cultures contain higher numbers of tumor-initiating cells than
adherent cell cultures and are able to establish a cellular heterogeneity closely
resembling that of patients’ tumors [51, 132, 203]. Because melanomaspheres
can readily be generated both from fresh tumor biopsies and cell lines passaged
as adherent cultures, this method is applicable to a large variety of samples.
Metastasis
Most patients die of metastatic disease and not of primary tumor growth [204].
Therefore, we also assessed systemic metastatic spread upon transplantation
by checking all animals for metastatic lesions in the inguinal and axillary
lymph nodes, lung, intestine and liver. Unfortunately, no macroscopic visceral
metastases were found in the range of this study. Considering that metastatic
disease is a rare event, which in humans can take decades to evolve [204], we
did not expect to find distant metastases already after 42 days in-vivo. How-
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ever, whether single tumor cells are already present in the internal organs at
the time point analyzed could not concludingly be determined and is subject
to further investigations.
The effect of a humanized environment
In contrast to previously described model systems [107, 125, 185], we use
organotypic skin substitutes as the basis for an orthotopic in-vivo model. This
approach offers the advantage to reconstruct skin grafts from distinct cellular
components, allowing the engineering of a fully humanized organotypic envi-
ronment. Moreover, all cell types used for melanoma reconstruction can be
manipulated, including the melanoma cells, the keratinocytes, and the dermal
fibroblasts. This, for the first time, will allow in-vivo studies addressing the
influence of a human microenvironment on tumor progression in a defined ex-
perimental set-up. The significance of such studies becomes apparent by our
observation that the humanized dermal compartment clearly exerted a favor-
able effect on tumor growth as compared to the neighboring rat tissue. Given
the known influence of stromal fibroblast on tumor growth and progression
[187, 188, 189], the use of a fully humanized dermal compartment containing
human fibroblasts is therefore favorable over a chimeric dermal compartment
that results from the repopulation of devitalized human dermal substrate with
recipient animal fibroblasts [125, 103, 186].
The influence of the microenvironment has to be considered in particular when
studying tumorigenesis in subcutaneous xenografts [50, 49, 135]. Subcuta-
neous injections are placed into the subdermal compartment, which according
to our findings represents an unphysiological environment for tumor growth
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and is associated with extensive necrosis in the transplanted tumor tissue.
Thus, recent controversial findings regarding the nature of melanoma-initiating
cells [50, 49, 135, 107, 106, 71] may indeed partly be attributed to the use of
subcutaneous xenografts in some of these studies [70]. Moreover, apart from
creating an unphysiological environment, subcutaneous xenografts do not re-
capitulate the invasive behavior of melanoma [103], and thus, should not be
considered an orthotopic model system. As a result, it has been suggested
that studies performed with human samples should be validated in a human-
ized in-vivo environment [53]. A recent report has used intradermal injections
into human foreskin grafts [107]. However, like subcutaneous injections, in-
tradermal inoculation cannot entirely reproduce the early stages of tumor
progression. This is because the initial influence of the microenvironment and
the crucial switch from radial to vertical growth are sidestepped upon dermal
seeding of melanoma cells. Thus, even if applied into the context of a hu-
man skin graft, also intradermal injections do not represent a fully orthotopic
model system.
The immune system
Even though our model closely mimics human disease progression, the use
of immunocompromized recipient animals for transplantation creates the in-
herent problem of an incomplete immune system. As the immune system is
considered to have an important impact on growth and progression of tumors,
including human melanoma [51, 205, 206, 207], this aspect falls short in every
model system using human cells. Indeed, only few host macrophages and NK
cells were found close to or within the reconstituted human tumors in our
model system (data not shown). Despite this limitation, we feel that the use
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of human patient samples remains crucial for the development of therapeutics
targeting human cancer cells. This is particularly relevant given the dramati-
cally different architecture of human and rodent skin, with human melanocytes
mainly residing in the interfollicular epidermis and rodent melanocytes being
mostly confined to hair follicles [103]. Therefore, although crucial for the
identification of molecular processes involved in tumorigenesis, genetic mouse
melanoma models only approximate the human disease [194] impeding their
direct translation to the clinic.
Advantages for future studies
In contrast to other approaches, the model system described here allows the
faithful recapitulation of the central steps of human melanoma growth and
progression in a physiological, humanized environment in-vivo. This in turn
will help to translate basic research into a clinically more relevant context by
providing the opportunity to devise and test therapeutics in a model system
closely resembling the human disease. Furthermore, it retains the possibility
to experimentally influence every single cell type in the system, which will al-
low manifold strategies to study the interactions between the tumor cells and
the surrounding microenvironment. As a proof of principle we addressed the
functional role of E-cadherin in melanoma progression. Whereas in subcuta-
neous xenografts no difference upon loss of E-cadherin was observed (data not
shown), using the same samples in a reconstitution approach induced a dra-
matic effect on tumor integrity (Figure 34). This clearly shows the advantage
of an orthotopic model in studying tumor progression. Especially if consid-
ering that, although the loss of E-cadherin has been implicated in melanoma
progression for over a decade [182, 197], this is the first evidence validating
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these findings in-vivo. Thus, given these promising results, we are convinced
that the model system developed in the range of this thesis harbors a great
potential for future studies.
Limitations
Nevertheless, there remain some technical limitations that have to be taken
into consideration. Originally developed as a preclinical model for human
skin grafts, the surgical procedure and the resulting animal care is cumber-
some. This fact limits the amount of animals available for studies dramatically,
making functional analyses difficult and time consuming to realize. Whereas
it remains feasible to investigate few targets at a time, the system will not
prove suitable for larger screening approaches. However, considering the orig-
inal incentive underlying its development, namely to study the implication of
multiple EMT target genes in the metastatic process, this represents a sever
limitation. Therefore, with respect to future screening approaches, addition-
ally establishing the same procedure in a mouse model should be considered.
Given similar approaches using human foreskin grafts [107, 185] or devitalized
skin substrates [125] in mice, a transfer should be technically feasible. With
regard to that, a major advantage would be gained by establishing an alterna-
tive to the used metal rings. Being delicate and labor intensive, establishing
a more practical solution, for examples using silicon Boyden chambers, could
significantly facilitate subsequent animal care.
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Melanoma stem cells in the reconstituted skin model
Following the conflicting reports surrounding the hierarchical organization of
melanoma [50, 49, 135, 107, 106, 71, 66], it was suggested that studies per-
formed with human samples should be validated in a humanized in-vivo en-
vironment [53, 48]. To follow up on this suggestion, we chose to test the
previously described MSC marker CD271 [51, 107] in our skin reconstitution
model. To this end we assessed the tumor induction potential of CD271Pos,
CD271Neg, or unsorted melanoma cells in transplanted skin substitutes. How-
ever, in contrast to the reports affirming CD271 as a MSC marker [51, 107],
no difference regarding their tumor induction potential was observed (Figure
26b). Although we cannot entirely exclude a potential contamination of the
negative fraction with CD271Pos cells, it appears an unlikely explanation for
the observed result. This is because, even in case of a contamination, still
comparatively few cells would be present in the negative fraction given their
flow-cytometric profile (Figure 26a). Considering that in this case the negative
cells exceed the contaminating positive cells by several orders of magnitude,
one would expect this imbalance to manifest in a slower growth kinetic. As
this was not found to be the case, it appears that in this experimental system
CD271 does not discriminate cells with an exclusive tumor induction potential.
However, whether this lack of hierarchical organization has to be considered
a direct effect of the orthotopic environment or simply reflects the use of a
’wrong’ MSC marker remains to be determined.
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Melanoma cell plasticity
In line with the theory suggesting that tumors are not static entities [53, 48,
66], we found some preliminary evidence pointing to a potential dynamic reg-
ulation of MSCs. The first evidence came from the finding that all tumors,
irrespective of whether they originated from a CD271Pos, CD271Neg or un-
sorted population, contained cells positive for the MSC markers CD271 and
Sox10 (Figure 27). Even though the most logic interpretation for this simply
points to an alternative MSC population heterogeneously expressing CD271,
two convincing arguments contradict this conclusion. First, the robust neural
crest phenotype consistently found across several patients [51] points to the
implication of a neural crest stem cell-like cell in melanoma growth. Given
the identification of such a population on the basis of the neural crest marker
CD271 in two independent studies [51, 107], CD271 represents the most plausi-
ble candidate. And second, CD271/Sox10 expression was shown to be directly
correlated with survival and metastasis in patients [51] (Figure 17). If these
arguments are considered in the context of a potential dynamic regulation of
the MSC population, an interesting concept evolves. Similar to the findings
in breast cancer [72, 73], in this model extrinsic cues could be able to govern
metastatic dissemination of melanoma cells by inducing stem-cell traits. In-
triguingly, the ramifications of this hypothesis would allow to reconcile many
disparate findings surrounding the nature and abundance of melanoma stem
cells. As such the stem-cell characteristics found in a particular sample would
be dependent on the origin of the sample (primary vs. metastasis), the stage
of the tumor, the amount of disseminated cells, the used model system etc.
Thus, to test whether CD271 can be dynamically expressed in human mel-
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anoma, we established a novel time-lapse technique. Using whole pieces of
subcutaneous xenografts allowed us to follow single cells leaving their intact
tumor microenvironment with high temporal resolution (Figure 28). Based
on this technique, we were able to confirm a dynamic expression of CD271 in
some emigrating melanoma cells (Figure 29). However, although these findings
show that CD271 expression can be upregulated in human melanoma cells, it
could not be determined whether these cells also acquired stem-cell features
in the process. To test this, some means allowing the prospective isolation of
cell acquiring CD271 expression would have to be implemented into the exper-
imental set-up, which proved technically not feasible in the range of this study.
Neural crest EMT signaling pathways in melanoma metastasis
Supported by recent findings in breast cancer [72, 73], a process reminiscent of
neural crest EMT presently appears to be the most promising candidate able
to induce the potential acquisition of stem-cell characteristics in melanoma.
Intriguingly, taking into account that EMT is also considered a determinant of
malignant progression, validation of this theory would establish a direct link
between the acquisition of stem-cell traits and metastasis. Strikingly, in favor
of this theory, several studies have implicated CD271 in melanoma invasion
and metastasis [145, 146, 147, 148, 149, 107, 51].
Thus, to address a potential link between CD271 expression, EMT, and inva-
sion, we assessed CD271 expression in reconstituted tumors. Whereas it was
found to be sporadically upregulated at the invasive front in some samples
(Figure 25b), the most prominent effect was observed in response to loss of
E-cadherin. Showing highly invasive, scattered tumors, CD271 was strongly
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expressed throughout all samples analyzed (N=2 animals) (Figure 36). Inter-
estingly, the same expression pattern was also found in invasive tumors of the
control sample (Figure 35), which substantiated the implication of CD271 pos-
itive cells in invasion. However, although these preliminary findings point to
a correlation between EMT, loss of E-cadherin, gain of CD271, and invasion,
loss of E-cadherin was not found to directly induce CD271 expression in-vitro
(Figure 33b,c). And moreover, whether the observed invasive cells positive for
CD271 represent true stem-cells in the sense of self-renewal and differentiation
capacity also remains to be addressed.
The functional role of CD271
Given the preliminary findings suggesting a role for CD271 positive cells in
invasion, we addressed whether CD271 in its function as a TNF receptor fam-
ily member directly influences the invasive behavior of melanoma cells in-vivo.
But questioning a prominent function of CD271, no striking differences in
terms of tumor size and morphology was found upon transplantation of cells
overexpression CD271 (Figure 31). Nevertheless, the samples overexpressing
CD271 (N=2 animals) showed an increased ability to seed satellite metastases
in the subdermal rat tissue, an effect not observed before. However, to what
extend this reflected an enhanced invasive or survival potential in response to
CD271 expression needs to be validated in additional experiments. Along this
line, especially the functional ablation of CD271 expression would yield more
relevant information with respect to the functionality of CD271.
In conclusion, the results obtained in the range of this thesis point to the
functional implication of neural crest pathways in melanoma metastasis. As
such loss of E-cadherin was shown to induce invasive growth in-vivo, whereas
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expression of CD271 was found to be highly expressed on invasive cells. Al-
though most of these functional results are preliminary, they clearly show
the potential of the developed model system to study melanoma progression.
Taken together with the construction of several lentiviral vectors targeting
neural crest EMT pathways, this project presents a first step towards a better
understanding of the most deadly form of skin cancer.
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Neural crest EMT signaling pathways in melanoma
metastasis
With respect to the functional contribution of neural crest EMT pathways in
the metastatic process, a variety of lentiviral vectors have been constructed
in the range of this study (Figure 31). Testing these on the basis of the re-
constituted skin model will yield further insights into their implication in the
metastatic process.
Given the promising results with respect to loss of E-cadherin, these findings
have to validated in statistic relevant numbers using different patient sam-
ples. Along this line, to confirm the role of E-cadherin as a determinant of
melanoma invasion also the effect of E-cadherin gain-of-function experiments
should be assessed.
Considering the unclear results obtained by overexpressing CD271, loss-of-
function experiments might prove the more promising approach to elucidate
the functional role of CD271 in melanoma growth and progression.
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Microarray analysis
Considering the preliminary findings implicating the loss of E-cadherin and
an upregulation of CD271 in melanoma invasion, it would be interesting to
assess to what extend these populations are intrinsically different from each
other. However, given the lack of suitable in-vivo model systems for mela-
noma progression, addressing these differences has not been possible so far.
Thus, based on our reconstitution approach we currently conduct a study to
address the nature of CD271Pos and E-cadNeg cells in-vivo. To this end we
116
Microarray analysis
take advantage of the fact that our model not only recapitulates disease pro-
gression, but also allows the unequivocal isolation of GFP expressing tumor
cells. This will allow us to fractionate a reconstituted tumor in GFP/CD271Pos
vs. GFP/CD271Neg and GFP/E-cadPos vs. GFP/E-cadNeg populations using
FACS. Subjecting the resulting fractions to microarray analysis will allow us
to address central questions regarding E-cadherin as a determinant of EMT
and CD271 as a MSC marker. Along this line it will be especially interest-
ing to assess whether E-cadNeg cells show a mesenchymal expression profile as
compared to E-cadPos cells and whether the CD271Pos expression pattern can
be correlated to that of neural crest stem cells.
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